id	sid	tid	token	lemma	pos
dpc-4159	1	1	dermatology	dermatology	NOUN
dpc-4159	1	2	:	:	PUNCT
dpc-4159	1	3	practical	practical	ADJ
dpc-4159	1	4	and	and	CCONJ
dpc-4159	1	5	conceptual	conceptual	ADJ
dpc-4159	1	6	research	research	NOUN
dpc-4159	1	7	letter	letter	NOUN
dpc-4159	2	1	|	|	ADV
dpc-4159	2	2	dermatol	dermatol	ADJ
dpc-4159	2	3	pract	pract	NOUN
dpc-4159	2	4	concept	concept	NOUN
dpc-4159	2	5	.	.	PUNCT
dpc-4159	3	1	2024;14(3):e2024179	2024;14(3):e2024179	NUM
dpc-4159	3	2	1	1	NUM
dpc-4159	3	3	real	real	ADJ
dpc-4159	3	4	life	life	NOUN
dpc-4159	3	5	comparative	comparative	ADJ
dpc-4159	3	6	effectiveness	effectiveness	NOUN
dpc-4159	3	7	of	of	ADP
dpc-4159	3	8	il-23	il-23	NOUN
dpc-4159	3	9	inhibitors	inhibitor	NOUN
dpc-4159	3	10	in	in	ADP
dpc-4159	3	11	the	the	DET
dpc-4159	3	12	treatment	treatment	NOUN
dpc-4159	3	13	of	of	ADP
dpc-4159	3	14	moderate	moderate	ADJ
dpc-4159	3	15	to	to	ADP
dpc-4159	3	16	severe	severe	ADJ
dpc-4159	3	17	psoriasis	psoriasis	NOUN
dpc-4159	3	18	:	:	PUNCT
dpc-4159	3	19	a	a	DET
dpc-4159	3	20	multicenter	multicenter	ADJ
dpc-4159	3	21	experience	experience	NOUN
dpc-4159	3	22	alessandro	alessandro	PROPN
dpc-4159	3	23	borghi1	borghi1	PROPN
dpc-4159	3	24	,	,	PUNCT
dpc-4159	3	25	giulia	giulia	PROPN
dpc-4159	3	26	odorici1	odorici1	PROPN
dpc-4159	3	27	,	,	PUNCT
dpc-4159	3	28	federico	federico	PROPN
dpc-4159	3	29	bardazzi2	bardazzi2	PROPN
dpc-4159	3	30	,	,	PUNCT
dpc-4159	3	31	federica	federica	PROPN
dpc-4159	3	32	filippi2	filippi2	PROPN
dpc-4159	3	33	,	,	PUNCT
dpc-4159	3	34	laura	laura	PROPN
dpc-4159	3	35	bigi3	bigi3	PROPN
dpc-4159	3	36	,	,	PUNCT
dpc-4159	3	37	claudia	claudia	PROPN
dpc-4159	3	38	lasagni3	lasagni3	PROPN
dpc-4159	3	39	,	,	PUNCT
dpc-4159	3	40	marco	marco	PROPN
dpc-4159	3	41	manfredini3	manfredini3	PROPN
dpc-4159	3	42	,	,	PUNCT
dpc-4159	3	43	vito	vito	PROPN
dpc-4159	3	44	di	di	PROPN
dpc-4159	3	45	lernia4	lernia4	PROPN
dpc-4159	3	46	,	,	PUNCT
dpc-4159	3	47	francesca	francesca	PROPN
dpc-4159	3	48	peccerillo4	peccerillo4	PROPN
dpc-4159	3	49	,	,	PUNCT
dpc-4159	3	50	andrea	andrea	PROPN
dpc-4159	3	51	conti5	conti5	PROPN
dpc-4159	3	52	,	,	PUNCT
dpc-4159	3	53	rossana	rossana	PROPN
dpc-4159	3	54	tiberio5	tiberio5	PROPN
dpc-4159	3	55	,	,	PUNCT
dpc-4159	3	56	francesca	francesca	PROPN
dpc-4159	3	57	satolli6	satolli6	PROPN
dpc-4159	3	58	,	,	PUNCT
dpc-4159	3	59	carolina	carolina	PROPN
dpc-4159	3	60	fantini6	fantini6	NOUN
dpc-4159	3	61	,	,	PUNCT
dpc-4159	3	62	miriam	miriam	PROPN
dpc-4159	3	63	rovesti7	rovesti7	PROPN
dpc-4159	3	64	,	,	PUNCT
dpc-4159	3	65	massimo	massimo	PROPN
dpc-4159	3	66	gasperini7	gasperini7	PROPN
dpc-4159	3	67	,	,	PUNCT
dpc-4159	3	68	michela	michela	PROPN
dpc-4159	3	69	tabanelli8	tabanelli8	PROPN
dpc-4159	3	70	,	,	PUNCT
dpc-4159	3	71	simone	simone	PROPN
dpc-4159	3	72	d’adamio8	d’adamio8	PROPN
dpc-4159	3	73	,	,	PUNCT
dpc-4159	3	74	maria	maria	PROPN
dpc-4159	3	75	elena	elena	PROPN
dpc-4159	3	76	flacco9	flacco9	PROPN
dpc-4159	3	77	,	,	PUNCT
dpc-4159	3	78	monica	monica	PROPN
dpc-4159	3	79	corazza1	corazza1	PROPN
dpc-4159	3	80	1	1	NUM
dpc-4159	3	81	section	section	NOUN
dpc-4159	3	82	of	of	ADP
dpc-4159	3	83	dermatology	dermatology	NOUN
dpc-4159	3	84	and	and	CCONJ
dpc-4159	3	85	infectious	infectious	ADJ
dpc-4159	3	86	diseases	disease	NOUN
dpc-4159	3	87	,	,	PUNCT
dpc-4159	3	88	department	department	NOUN
dpc-4159	3	89	of	of	ADP
dpc-4159	3	90	medical	medical	ADJ
dpc-4159	3	91	sciences	sciences	PROPN
dpc-4159	3	92	,	,	PUNCT
dpc-4159	3	93	university	university	NOUN
dpc-4159	3	94	of	of	ADP
dpc-4159	3	95	ferrara	ferrara	NOUN
dpc-4159	3	96	,	,	PUNCT
dpc-4159	3	97	ferrara	ferrara	NOUN
dpc-4159	3	98	,	,	PUNCT
dpc-4159	3	99	italy	italy	PROPN
dpc-4159	3	100	2	2	NUM
dpc-4159	3	101	dermatology	dermatology	NOUN
dpc-4159	3	102	unit	unit	NOUN
dpc-4159	3	103	,	,	PUNCT
dpc-4159	3	104	irccs	irccs	PROPN
dpc-4159	3	105	azienda	azienda	PROPN
dpc-4159	3	106	ospedaliero	ospedaliero	PROPN
dpc-4159	3	107	-	-	PUNCT
dpc-4159	3	108	universitaria	universitaria	PROPN
dpc-4159	3	109	di	di	PROPN
dpc-4159	3	110	bologna	bologna	PROPN
dpc-4159	3	111	,	,	PUNCT
dpc-4159	3	112	policlinico	policlinico	PROPN
dpc-4159	3	113	s.	s.	PROPN
dpc-4159	3	114	orsola	orsola	PROPN
dpc-4159	3	115	-	-	PUNCT
dpc-4159	3	116	malpighi	malpighi	PROPN
dpc-4159	3	117	,	,	PUNCT
dpc-4159	3	118	bologna	bologna	PROPN
dpc-4159	3	119	,	,	PUNCT
dpc-4159	3	120	italy	italy	PROPN
dpc-4159	3	121	3	3	NUM
dpc-4159	3	122	dermatology	dermatology	NOUN
dpc-4159	3	123	unit	unit	NOUN
dpc-4159	3	124	,	,	PUNCT
dpc-4159	3	125	department	department	NOUN
dpc-4159	3	126	of	of	ADP
dpc-4159	3	127	surgical	surgical	ADJ
dpc-4159	3	128	,	,	PUNCT
dpc-4159	3	129	medical	medical	ADJ
dpc-4159	3	130	,	,	PUNCT
dpc-4159	3	131	dental	dental	ADJ
dpc-4159	3	132	and	and	CCONJ
dpc-4159	3	133	morphological	morphological	ADJ
dpc-4159	3	134	sciences	science	NOUN
dpc-4159	3	135	related	relate	VERB
dpc-4159	3	136	to	to	ADP
dpc-4159	3	137	transplant	transplant	NOUN
dpc-4159	3	138	,	,	PUNCT
dpc-4159	3	139	oncology	oncology	NOUN
dpc-4159	3	140	and	and	CCONJ
dpc-4159	3	141	regenerative	regenerative	ADJ
dpc-4159	3	142	medicine	medicine	NOUN
dpc-4159	3	143	,	,	PUNCT
dpc-4159	3	144	university	university	NOUN
dpc-4159	3	145	of	of	ADP
dpc-4159	3	146	modena	modena	PROPN
dpc-4159	3	147	and	and	CCONJ
dpc-4159	3	148	reggio	reggio	PROPN
dpc-4159	3	149	emilia	emilia	PROPN
dpc-4159	3	150	,	,	PUNCT
dpc-4159	3	151	modena	modena	PROPN
dpc-4159	3	152	,	,	PUNCT
dpc-4159	3	153	italy	italy	PROPN
dpc-4159	3	154	4	4	NUM
dpc-4159	3	155	dermatology	dermatology	NOUN
dpc-4159	3	156	unit	unit	NOUN
dpc-4159	3	157	,	,	PUNCT
dpc-4159	3	158	arcispedale	arcispedale	PROPN
dpc-4159	3	159	santa	santa	PROPN
dpc-4159	3	160	maria	maria	PROPN
dpc-4159	3	161	nuova	nuova	PROPN
dpc-4159	3	162	,	,	PUNCT
dpc-4159	3	163	azienda	azienda	PROPN
dpc-4159	3	164	usl	usl	PROPN
dpc-4159	3	165	-	-	PUNCT
dpc-4159	3	166	irccs	irccs	NOUN
dpc-4159	3	167	di	di	PROPN
dpc-4159	3	168	reggio	reggio	PROPN
dpc-4159	3	169	emilia	emilia	PROPN
dpc-4159	3	170	,	,	PUNCT
dpc-4159	3	171	reggio	reggio	PROPN
dpc-4159	3	172	emilia	emilia	PROPN
dpc-4159	3	173	,	,	PUNCT
dpc-4159	3	174	italy	italy	PROPN
dpc-4159	3	175	5	5	NUM
dpc-4159	3	176	dermatology	dermatology	NOUN
dpc-4159	3	177	unit	unit	NOUN
dpc-4159	3	178	,	,	PUNCT
dpc-4159	3	179	infermi	infermi	NOUN
dpc-4159	3	180	hospital	hospital	NOUN
dpc-4159	3	181	,	,	PUNCT
dpc-4159	3	182	rimini	rimini	PROPN
dpc-4159	3	183	,	,	PUNCT
dpc-4159	3	184	ausl	ausl	PROPN
dpc-4159	3	185	romagna	romagna	PROPN
dpc-4159	3	186	,	,	PUNCT
dpc-4159	3	187	italy	italy	PROPN
dpc-4159	3	188	6	6	NUM
dpc-4159	3	189	section	section	NOUN
dpc-4159	3	190	of	of	ADP
dpc-4159	3	191	dermatology	dermatology	NOUN
dpc-4159	3	192	,	,	PUNCT
dpc-4159	3	193	department	department	NOUN
dpc-4159	3	194	of	of	ADP
dpc-4159	3	195	medicine	medicine	NOUN
dpc-4159	3	196	and	and	CCONJ
dpc-4159	3	197	surgery	surgery	NOUN
dpc-4159	3	198	,	,	PUNCT
dpc-4159	3	199	university	university	NOUN
dpc-4159	3	200	of	of	ADP
dpc-4159	3	201	parma	parma	PROPN
dpc-4159	3	202	,	,	PUNCT
dpc-4159	3	203	parma	parma	PROPN
dpc-4159	3	204	,	,	PUNCT
dpc-4159	3	205	italy	italy	PROPN
dpc-4159	3	206	7	7	NUM
dpc-4159	3	207	dermatologic	dermatologic	ADJ
dpc-4159	3	208	unit	unit	NOUN
dpc-4159	3	209	,	,	PUNCT
dpc-4159	3	210	ospedale	ospedale	PROPN
dpc-4159	3	211	“	"	PUNCT
dpc-4159	3	212	guglielmo	guglielmo	PROPN
dpc-4159	3	213	da	da	PROPN
dpc-4159	3	214	saliceto	saliceto	PROPN
dpc-4159	3	215	”	"	PUNCT
dpc-4159	3	216	di	di	NOUN
dpc-4159	3	217	piacenza	piacenza	PROPN
dpc-4159	3	218	pc	pc	PROPN
dpc-4159	3	219	,	,	PUNCT
dpc-4159	3	220	italy	italy	PROPN
dpc-4159	3	221	8	8	NUM
dpc-4159	3	222	uoc	uoc	PROPN
dpc-4159	3	223	dermatology	dermatology	NOUN
dpc-4159	3	224	of	of	ADP
dpc-4159	3	225	ravenna	ravenna	PROPN
dpc-4159	3	226	,	,	PUNCT
dpc-4159	3	227	lugo	lugo	NOUN
dpc-4159	3	228	and	and	CCONJ
dpc-4159	3	229	faenza	faenza	ADJ
dpc-4159	3	230	,	,	PUNCT
dpc-4159	3	231	italy	italy	PROPN
dpc-4159	3	232	9	9	NUM
dpc-4159	3	233	department	department	NOUN
dpc-4159	3	234	of	of	ADP
dpc-4159	3	235	environmental	environmental	ADJ
dpc-4159	3	236	and	and	CCONJ
dpc-4159	3	237	prevention	prevention	NOUN
dpc-4159	3	238	sciences	sciences	PROPN
dpc-4159	3	239	,	,	PUNCT
dpc-4159	3	240	university	university	NOUN
dpc-4159	3	241	of	of	ADP
dpc-4159	3	242	ferrara	ferrara	NOUN
dpc-4159	3	243	,	,	PUNCT
dpc-4159	3	244	ferrara	ferrara	NOUN
dpc-4159	3	245	,	,	PUNCT
dpc-4159	3	246	italy	italy	PROPN
dpc-4159	3	247	key	key	ADJ
dpc-4159	3	248	words	word	NOUN
dpc-4159	3	249	:	:	PUNCT
dpc-4159	3	250	psoriasis	psoriasis	NOUN
dpc-4159	3	251	,	,	PUNCT
dpc-4159	3	252	il23	il23	PROPN
dpc-4159	3	253	inhibitors	inhibitor	NOUN
dpc-4159	3	254	,	,	PUNCT
dpc-4159	3	255	therapy	therapy	NOUN
dpc-4159	3	256	,	,	PUNCT
dpc-4159	3	257	effectiveness	effectiveness	NOUN
dpc-4159	3	258	,	,	PUNCT
dpc-4159	3	259	retention	retention	NOUN
dpc-4159	3	260	rate	rate	NOUN
dpc-4159	3	261	,	,	PUNCT
dpc-4159	3	262	real	real	ADJ
dpc-4159	3	263	life	life	NOUN
dpc-4159	3	264	citation	citation	NOUN
dpc-4159	3	265	:	:	PUNCT
dpc-4159	3	266	borghi	borghi	PROPN
dpc-4159	3	267	a	a	PRON
dpc-4159	3	268	,	,	PUNCT
dpc-4159	3	269	odorici	odorici	NOUN
dpc-4159	3	270	g	g	NOUN
dpc-4159	3	271	,	,	PUNCT
dpc-4159	3	272	bardazzi	bardazzi	NOUN
dpc-4159	3	273	f	f	PROPN
dpc-4159	3	274	,	,	PUNCT
dpc-4159	3	275	et	et	PROPN
dpc-4159	3	276	al	al	PROPN
dpc-4159	3	277	.	.	PUNCT
dpc-4159	4	1	real	real	ADJ
dpc-4159	4	2	life	life	NOUN
dpc-4159	4	3	comparative	comparative	ADJ
dpc-4159	4	4	effectiveness	effectiveness	NOUN
dpc-4159	4	5	of	of	ADP
dpc-4159	4	6	il-23	il-23	NOUN
dpc-4159	4	7	inhibitors	inhibitor	NOUN
dpc-4159	4	8	in	in	ADP
dpc-4159	4	9	the	the	DET
dpc-4159	4	10	treatment	treatment	NOUN
dpc-4159	4	11	of	of	ADP
dpc-4159	4	12	moderate	moderate	ADJ
dpc-4159	4	13	to	to	ADP
dpc-4159	4	14	severe	severe	ADJ
dpc-4159	4	15	psoriasis	psoriasis	NOUN
dpc-4159	4	16	:	:	PUNCT
dpc-4159	4	17	a	a	DET
dpc-4159	4	18	multicenter	multicenter	ADJ
dpc-4159	4	19	experience	experience	NOUN
dpc-4159	4	20	.	.	PUNCT
dpc-4159	5	1	dermatol	dermatol	NOUN
dpc-4159	5	2	pract	pract	PROPN
dpc-4159	5	3	concept	concept	NOUN
dpc-4159	5	4	.	.	PUNCT
dpc-4159	6	1	2024;14(3):e2024179	2024;14(3):e2024179	NUM
dpc-4159	6	2	.	.	PUNCT
dpc-4159	7	1	doi	doi	NOUN
dpc-4159	7	2	:	:	PUNCT
dpc-4159	7	3	https://doi.org/10.5826/dpc.1403a179	https://doi.org/10.5826/dpc.1403a179	NOUN
dpc-4159	7	4	accepted	accept	VERB
dpc-4159	7	5	:	:	PUNCT
dpc-4159	7	6	march	march	PROPN
dpc-4159	7	7	25	25	NUM
dpc-4159	7	8	,	,	PUNCT
dpc-4159	7	9	2024	2024	NUM
dpc-4159	7	10	;	;	PUNCT
dpc-4159	7	11	published	publish	VERB
dpc-4159	7	12	:	:	PUNCT
dpc-4159	8	1	july	july	PROPN
dpc-4159	8	2	2024	2024	NUM
dpc-4159	8	3	copyright	copyright	NOUN
dpc-4159	8	4	:	:	PUNCT
dpc-4159	8	5	©	©	PROPN
dpc-4159	8	6	2024	2024	NUM
dpc-4159	8	7	borghi	borghi	PROPN
dpc-4159	8	8	et	et	PROPN
dpc-4159	8	9	al	al	PROPN
dpc-4159	8	10	.	.	PUNCT
dpc-4159	9	1	this	this	PRON
dpc-4159	9	2	is	be	AUX
dpc-4159	9	3	an	an	DET
dpc-4159	9	4	open	open	ADJ
dpc-4159	9	5	-	-	PUNCT
dpc-4159	9	6	access	access	NOUN
dpc-4159	9	7	article	article	NOUN
dpc-4159	9	8	distributed	distribute	VERB
dpc-4159	9	9	under	under	ADP
dpc-4159	9	10	the	the	DET
dpc-4159	9	11	terms	term	NOUN
dpc-4159	9	12	of	of	ADP
dpc-4159	9	13	the	the	DET
dpc-4159	9	14	creative	creative	ADJ
dpc-4159	9	15	commons	common	NOUN
dpc-4159	9	16	attributionnoncommercial	attributionnoncommercial	ADJ
dpc-4159	9	17	license	license	NOUN
dpc-4159	9	18	(	(	PUNCT
dpc-4159	9	19	by	by	ADP
dpc-4159	9	20	-	-	PUNCT
dpc-4159	9	21	nc-4.0	nc-4.0	NOUN
dpc-4159	9	22	)	)	PUNCT
dpc-4159	9	23	,	,	PUNCT
dpc-4159	9	24	https://creativecommons.org/licenses/by-nc/4.0/	https://creativecommons.org/licenses/by-nc/4.0/	PROPN
dpc-4159	9	25	,	,	PUNCT
dpc-4159	9	26	which	which	PRON
dpc-4159	9	27	permits	permit	VERB
dpc-4159	9	28	unrestricted	unrestricted	ADJ
dpc-4159	9	29	noncommercial	noncommercial	ADJ
dpc-4159	9	30	use	use	NOUN
dpc-4159	9	31	,	,	PUNCT
dpc-4159	9	32	distribution	distribution	NOUN
dpc-4159	9	33	,	,	PUNCT
dpc-4159	9	34	and	and	CCONJ
dpc-4159	9	35	reproduction	reproduction	NOUN
dpc-4159	9	36	in	in	ADP
dpc-4159	9	37	any	any	DET
dpc-4159	9	38	medium	medium	NOUN
dpc-4159	9	39	,	,	PUNCT
dpc-4159	9	40	provided	provide	VERB
dpc-4159	9	41	the	the	DET
dpc-4159	9	42	original	original	ADJ
dpc-4159	9	43	authors	author	NOUN
dpc-4159	9	44	and	and	CCONJ
dpc-4159	9	45	source	source	NOUN
dpc-4159	9	46	are	be	AUX
dpc-4159	9	47	credited	credit	VERB
dpc-4159	9	48	.	.	PUNCT
dpc-4159	10	1	funding	funding	NOUN
dpc-4159	10	2	:	:	PUNCT
dpc-4159	10	3	none	none	NOUN
dpc-4159	10	4	.	.	PUNCT
dpc-4159	11	1	competing	compete	VERB
dpc-4159	11	2	interests	interest	NOUN
dpc-4159	11	3	:	:	PUNCT
dpc-4159	11	4	none	none	NOUN
dpc-4159	11	5	.	.	PUNCT
dpc-4159	12	1	authorship	authorship	NOUN
dpc-4159	12	2	:	:	PUNCT
dpc-4159	12	3	all	all	DET
dpc-4159	12	4	authors	author	NOUN
dpc-4159	12	5	have	have	AUX
dpc-4159	12	6	contributed	contribute	VERB
dpc-4159	12	7	significantly	significantly	ADV
dpc-4159	12	8	to	to	ADP
dpc-4159	12	9	this	this	DET
dpc-4159	12	10	publication	publication	NOUN
dpc-4159	12	11	.	.	PUNCT
dpc-4159	13	1	alessandro	alessandro	PROPN
dpc-4159	13	2	borghi	borghi	PROPN
dpc-4159	13	3	and	and	CCONJ
dpc-4159	13	4	giulia	giulia	PROPN
dpc-4159	13	5	odorici	odorici	NOUN
dpc-4159	13	6	contributed	contribute	VERB
dpc-4159	13	7	equally	equally	ADV
dpc-4159	13	8	and	and	CCONJ
dpc-4159	13	9	share	share	VERB
dpc-4159	13	10	first	first	ADJ
dpc-4159	13	11	authorship	authorship	NOUN
dpc-4159	13	12	.	.	PUNCT
dpc-4159	14	1	maria	maria	PROPN
dpc-4159	14	2	elena	elena	PROPN
dpc-4159	14	3	flacco	flacco	PROPN
dpc-4159	14	4	and	and	CCONJ
dpc-4159	14	5	monica	monica	PROPN
dpc-4159	14	6	corazza	corazza	PROPN
dpc-4159	14	7	contributed	contribute	VERB
dpc-4159	14	8	equally	equally	ADV
dpc-4159	14	9	and	and	CCONJ
dpc-4159	14	10	share	share	VERB
dpc-4159	14	11	co	co	ADJ
dpc-4159	14	12	-	-	ADJ
dpc-4159	14	13	senior	senior	ADJ
dpc-4159	14	14	authorship	authorship	NOUN
dpc-4159	14	15	.	.	PUNCT
dpc-4159	15	1	corresponding	correspond	VERB
dpc-4159	15	2	author	author	NOUN
dpc-4159	15	3	:	:	PUNCT
dpc-4159	15	4	dr	dr	PROPN
dpc-4159	15	5	.	.	PROPN
dpc-4159	15	6	giulia	giulia	PROPN
dpc-4159	15	7	odorici	odorici	PROPN
dpc-4159	15	8	,	,	PUNCT
dpc-4159	15	9	uo	uo	NOUN
dpc-4159	15	10	dermatologia	dermatologia	NOUN
dpc-4159	15	11	,	,	PUNCT
dpc-4159	15	12	dipartimento	dipartimento	ADP
dpc-4159	15	13	ospedaliero	ospedaliero	NOUN
dpc-4159	15	14	oncologicomedico	oncologicomedico	NOUN
dpc-4159	15	15	specialistico	specialistico	PROPN
dpc-4159	15	16	,	,	PUNCT
dpc-4159	15	17	azienda	azienda	PROPN
dpc-4159	15	18	ospedaliero	ospedaliero	PROPN
dpc-4159	15	19	universitaria	universitaria	PROPN
dpc-4159	15	20	arcispedale	arcispedale	NOUN
dpc-4159	15	21	sant’anna	sant’anna	NOUN
dpc-4159	15	22	,	,	PUNCT
dpc-4159	15	23	via	via	ADP
dpc-4159	15	24	aldo	aldo	PROPN
dpc-4159	15	25	moro	moro	PROPN
dpc-4159	15	26	8	8	NUM
dpc-4159	15	27	,	,	PUNCT
dpc-4159	15	28	cona	cona	NOUN
dpc-4159	15	29	(	(	PUNCT
dpc-4159	15	30	fe	fe	NOUN
dpc-4159	15	31	)	)	PUNCT
dpc-4159	15	32	,	,	PUNCT
dpc-4159	15	33	italy	italy	PROPN
dpc-4159	15	34	.	.	PUNCT
dpc-4159	16	1	tel	tel	PROPN
dpc-4159	16	2	:	:	PUNCT
dpc-4159	16	3	(	(	PUNCT
dpc-4159	16	4	+39	+39	PROPN
dpc-4159	16	5	)	)	PUNCT
dpc-4159	16	6	0532/239684	0532/239684	NUM
dpc-4159	16	7	,	,	PUNCT
dpc-4159	16	8	fax	fax	NOUN
dpc-4159	16	9	:	:	PUNCT
dpc-4159	16	10	0039	0039	NUM
dpc-4159	16	11	0532/206791	0532/206791	NUM
dpc-4159	16	12	.	.	PUNCT
dpc-4159	17	1	e	e	X
dpc-4159	17	2	-	-	NOUN
dpc-4159	17	3	mail	mail	NOUN
dpc-4159	17	4	:	:	PUNCT
dpc-4159	18	1	giulai87@hotmail.com	giulai87@hotmail.com	X
dpc-4159	18	2	introduction	introduction	NOUN
dpc-4159	18	3	with	with	ADP
dpc-4159	18	4	the	the	DET
dpc-4159	18	5	aim	aim	NOUN
dpc-4159	18	6	of	of	ADP
dpc-4159	18	7	assessing	assess	VERB
dpc-4159	18	8	and	and	CCONJ
dpc-4159	18	9	comparing	compare	VERB
dpc-4159	18	10	il23	il23	PROPN
dpc-4159	18	11	inhibitors	inhibitor	NOUN
dpc-4159	18	12	’	'	PUNCT
dpc-4159	18	13	effectiveness	effectiveness	NOUN
dpc-4159	18	14	,	,	PUNCT
dpc-4159	18	15	safety	safety	NOUN
dpc-4159	18	16	and	and	CCONJ
dpc-4159	18	17	drug	drug	NOUN
dpc-4159	18	18	survival	survival	NOUN
dpc-4159	18	19	in	in	ADP
dpc-4159	18	20	a	a	DET
dpc-4159	18	21	real	real	ADJ
dpc-4159	18	22	life	life	NOUN
dpc-4159	18	23	setting	setting	NOUN
dpc-4159	18	24	,	,	PUNCT
dpc-4159	18	25	we	we	PRON
dpc-4159	18	26	performed	perform	VERB
dpc-4159	18	27	a	a	DET
dpc-4159	18	28	retrospective	retrospective	ADJ
dpc-4159	18	29	study	study	NOUN
dpc-4159	18	30	involving	involve	VERB
dpc-4159	18	31	all	all	DET
dpc-4159	18	32	psoriasis	psoriasis	NOUN
dpc-4159	18	33	centers	center	NOUN
dpc-4159	18	34	of	of	ADP
dpc-4159	18	35	emilia	emilia	PROPN
dpc-4159	18	36	romagna	romagna	PROPN
dpc-4159	18	37	,	,	PUNCT
dpc-4159	18	38	northern	northern	PROPN
dpc-4159	18	39	italy	italy	PROPN
dpc-4159	18	40	.	.	PUNCT
dpc-4159	19	1	case	case	NOUN
dpc-4159	19	2	presentation	presentation	NOUN
dpc-4159	19	3	all	all	DET
dpc-4159	19	4	427	427	NUM
dpc-4159	19	5	patients	patient	NOUN
dpc-4159	19	6	affected	affect	VERB
dpc-4159	19	7	with	with	ADP
dpc-4159	19	8	moderate	moderate	ADJ
dpc-4159	19	9	-	-	PUNCT
dpc-4159	19	10	to	to	ADP
dpc-4159	19	11	-	-	PUNCT
dpc-4159	19	12	severe	severe	ADJ
dpc-4159	19	13	psoriasis	psoriasis	NOUN
dpc-4159	19	14	who	who	PRON
dpc-4159	19	15	consecutively	consecutively	ADV
dpc-4159	19	16	underwent	undergo	VERB
dpc-4159	19	17	treatment	treatment	NOUN
dpc-4159	19	18	with	with	ADP
dpc-4159	19	19	anti	anti	ADJ
dpc-4159	19	20	il23	il23	PROPN
dpc-4159	19	21	drugs	drug	NOUN
dpc-4159	19	22	from	from	ADP
dpc-4159	19	23	december	december	PROPN
dpc-4159	19	24	2018	2018	NUM
dpc-4159	19	25	to	to	ADP
dpc-4159	19	26	june	june	PROPN
dpc-4159	19	27	2022	2022	NUM
dpc-4159	19	28	were	be	AUX
dpc-4159	19	29	included	include	VERB
dpc-4159	19	30	.	.	PUNCT
dpc-4159	20	1	among	among	ADP
dpc-4159	20	2	them	they	PRON
dpc-4159	20	3	,	,	PUNCT
dpc-4159	20	4	201	201	NUM
dpc-4159	20	5	received	receive	VERB
dpc-4159	20	6	guselkumab	guselkumab	NOUN
dpc-4159	20	7	,	,	PUNCT
dpc-4159	20	8	116	116	NUM
dpc-4159	20	9	risankizumab	risankizumab	NOUN
dpc-4159	20	10	and	and	CCONJ
dpc-4159	20	11	110	110	NUM
dpc-4159	20	12	tildrakizumab	tildrakizumab	NOUN
dpc-4159	20	13	(	(	PUNCT
dpc-4159	20	14	table	table	NOUN
dpc-4159	20	15	1	1	NUM
dpc-4159	20	16	)	)	PUNCT
dpc-4159	20	17	.	.	PUNCT
dpc-4159	21	1	2	2	NUM
dpc-4159	21	2	research	research	NOUN
dpc-4159	21	3	letter	letter	NOUN
dpc-4159	21	4	|	|	ADV
dpc-4159	21	5	dermatol	dermatol	ADJ
dpc-4159	21	6	pract	pract	NOUN
dpc-4159	21	7	concept	concept	NOUN
dpc-4159	21	8	.	.	PUNCT
dpc-4159	22	1	2024;14(3):e2024179	2024;14(3):e2024179	NUM
dpc-4159	22	2	table	table	NOUN
dpc-4159	22	3	1	1	NUM
dpc-4159	22	4	.	.	NUM
dpc-4159	22	5	selected	select	VERB
dpc-4159	22	6	baseline	baseline	PROPN
dpc-4159	22	7	demographic	demographic	ADJ
dpc-4159	22	8	and	and	CCONJ
dpc-4159	22	9	clinical	clinical	ADJ
dpc-4159	22	10	characteristic	characteristic	NOUN
dpc-4159	22	11	of	of	ADP
dpc-4159	22	12	the	the	DET
dpc-4159	22	13	sample	sample	NOUN
dpc-4159	22	14	,	,	PUNCT
dpc-4159	22	15	overall	overall	ADV
dpc-4159	22	16	and	and	CCONJ
dpc-4159	22	17	by	by	ADP
dpc-4159	22	18	type	type	NOUN
dpc-4159	22	19	of	of	ADP
dpc-4159	22	20	anti	anti	ADJ
dpc-4159	22	21	-	-	ADJ
dpc-4159	22	22	il23	il23	PROPN
dpc-4159	22	23	.	.	PUNCT
dpc-4159	23	1	variables	variable	NOUN
dpc-4159	23	2	overall	overall	ADJ
dpc-4159	23	3	sample	sample	NOUN
dpc-4159	23	4	(	(	PUNCT
dpc-4159	23	5	n=427	n=427	NOUN
dpc-4159	23	6	)	)	PUNCT
dpc-4159	23	7	guselkumab	guselkumab	NOUN
dpc-4159	23	8	(	(	PUNCT
dpc-4159	23	9	n=201	n=201	NOUN
dpc-4159	23	10	)	)	PUNCT
dpc-4159	23	11	risankizumab	risankizumab	NOUN
dpc-4159	23	12	(	(	PUNCT
dpc-4159	23	13	n=116	n=116	NUM
dpc-4159	23	14	)	)	PUNCT
dpc-4159	23	15	tildrakizumab	tildrakizumab	NOUN
dpc-4159	23	16	(	(	PUNCT
dpc-4159	23	17	n=110	n=110	PROPN
dpc-4159	23	18	)	)	PUNCT
dpc-4159	24	1	p	p	X
dpc-4159	24	2	*	*	PUNCT
dpc-4159	24	3	mean	mean	ADJ
dpc-4159	24	4	age	age	NOUN
dpc-4159	24	5	in	in	ADP
dpc-4159	24	6	years	year	NOUN
dpc-4159	24	7	(	(	PUNCT
dpc-4159	24	8	sd	sd	NOUN
dpc-4159	24	9	)	)	PUNCT
dpc-4159	24	10	54.3	54.3	NUM
dpc-4159	24	11	(	(	PUNCT
dpc-4159	24	12	14.7	14.7	NUM
dpc-4159	24	13	)	)	PUNCT
dpc-4159	24	14	52.8	52.8	NUM
dpc-4159	24	15	(	(	PUNCT
dpc-4159	24	16	14.6	14.6	NUM
dpc-4159	24	17	)	)	PUNCT
dpc-4159	24	18	56.0	56.0	NUM
dpc-4159	24	19	(	(	PUNCT
dpc-4159	24	20	13.6	13.6	NUM
dpc-4159	24	21	)	)	PUNCT
dpc-4159	24	22	55.2	55.2	NUM
dpc-4159	24	23	(	(	PUNCT
dpc-4159	24	24	15.7	15.7	NUM
dpc-4159	24	25	)	)	PUNCT
dpc-4159	24	26	male	male	ADJ
dpc-4159	24	27	gender	gender	NOUN
dpc-4159	24	28	,	,	PUNCT
dpc-4159	24	29	%	%	NOUN
dpc-4159	24	30	63.2	63.2	NUM
dpc-4159	24	31	60.7	60.7	NUM
dpc-4159	24	32	62.9	62.9	NUM
dpc-4159	24	33	68.2	68.2	NUM
dpc-4159	24	34	mean	mean	NOUN
dpc-4159	24	35	bmi	bmi	NOUN
dpc-4159	24	36	(	(	PUNCT
dpc-4159	24	37	sd	sd	NOUN
dpc-4159	24	38	)	)	PUNCT
dpc-4159	24	39	27.9	27.9	NUM
dpc-4159	24	40	(	(	PUNCT
dpc-4159	24	41	5.2	5.2	NUM
dpc-4159	24	42	)	)	PUNCT
dpc-4159	24	43	27.8	27.8	NUM
dpc-4159	24	44	(	(	PUNCT
dpc-4159	24	45	5.4	5.4	NUM
dpc-4159	24	46	)	)	PUNCT
dpc-4159	24	47	27.9	27.9	NUM
dpc-4159	24	48	(	(	PUNCT
dpc-4159	24	49	5.0	5.0	NUM
dpc-4159	24	50	)	)	PUNCT
dpc-4159	24	51	28.2	28.2	NUM
dpc-4159	24	52	(	(	PUNCT
dpc-4159	24	53	5.0	5.0	NUM
dpc-4159	24	54	)	)	PUNCT
dpc-4159	24	55	current	current	ADJ
dpc-4159	24	56	smoker	smoker	NOUN
dpc-4159	24	57	,	,	PUNCT
dpc-4159	24	58	%	%	NOUN
dpc-4159	24	59	58.4	58.4	NUM
dpc-4159	24	60	49.4	49.4	NUM
dpc-4159	24	61	68.5	68.5	NUM
dpc-4159	24	62	63.6	63.6	NUM
dpc-4159	24	63	a	a	DET
dpc-4159	24	64	,	,	PUNCT
dpc-4159	24	65	b	b	NUM
dpc-4159	24	66	comorbidities	comorbiditie	NOUN
dpc-4159	24	67	,	,	PUNCT
dpc-4159	24	68	%	%	INTJ
dpc-4159	24	69	none	none	NOUN
dpc-4159	24	70	36.1	36.1	NUM
dpc-4159	24	71	36.3	36.3	NUM
dpc-4159	24	72	31.9	31.9	NUM
dpc-4159	24	73	40.0	40.0	NUM
dpc-4159	24	74	one	one	NUM
dpc-4159	24	75	43.3	43.3	NUM
dpc-4159	24	76	38.8	38.8	NUM
dpc-4159	24	77	50.9	50.9	NUM
dpc-4159	24	78	43.6	43.6	NUM
dpc-4159	24	79	a	a	DET
dpc-4159	24	80	two	two	NUM
dpc-4159	24	81	17.3	17.3	NUM
dpc-4159	24	82	19.4	19.4	NUM
dpc-4159	24	83	15.5	15.5	NUM
dpc-4159	24	84	15.5	15.5	NUM
dpc-4159	24	85	three	three	NUM
dpc-4159	24	86	or	or	CCONJ
dpc-4159	24	87	more	more	ADJ
dpc-4159	24	88	3.3	3.3	NUM
dpc-4159	24	89	5.5	5.5	NUM
dpc-4159	24	90	1.7	1.7	NUM
dpc-4159	24	91	0.9	0.9	NUM
dpc-4159	24	92	b	b	NOUN
dpc-4159	24	93	,	,	PUNCT
dpc-4159	24	94	c	c	NOUN
dpc-4159	24	95	mean	mean	VERB
dpc-4159	24	96	length	length	NOUN
dpc-4159	24	97	of	of	ADP
dpc-4159	24	98	disease	disease	NOUN
dpc-4159	24	99	in	in	ADP
dpc-4159	24	100	years	year	NOUN
dpc-4159	24	101	(	(	PUNCT
dpc-4159	24	102	sd	sd	NOUN
dpc-4159	24	103	)	)	PUNCT
dpc-4159	24	104	20.6	20.6	NUM
dpc-4159	24	105	(	(	PUNCT
dpc-4159	24	106	12.4	12.4	NUM
dpc-4159	24	107	)	)	PUNCT
dpc-4159	24	108	20.1	20.1	NUM
dpc-4159	24	109	(	(	PUNCT
dpc-4159	24	110	12.5	12.5	NUM
dpc-4159	24	111	)	)	PUNCT
dpc-4159	24	112	21.7	21.7	NUM
dpc-4159	24	113	(	(	PUNCT
dpc-4159	24	114	12.2	12.2	NUM
dpc-4159	24	115	)	)	PUNCT
dpc-4159	24	116	20.2	20.2	NUM
dpc-4159	24	117	(	(	PUNCT
dpc-4159	24	118	12.6	12.6	NUM
dpc-4159	24	119	)	)	PUNCT
dpc-4159	24	120	mean	mean	NOUN
dpc-4159	24	121	age	age	NOUN
dpc-4159	24	122	at	at	ADP
dpc-4159	24	123	onset	onset	NOUN
dpc-4159	24	124	(	(	PUNCT
dpc-4159	24	125	sd	sd	NOUN
dpc-4159	24	126	)	)	PUNCT
dpc-4159	24	127	33.3	33.3	NUM
dpc-4159	24	128	(	(	PUNCT
dpc-4159	24	129	16.0	16.0	NUM
dpc-4159	24	130	)	)	PUNCT
dpc-4159	24	131	32.3	32.3	NUM
dpc-4159	24	132	(	(	PUNCT
dpc-4159	24	133	16.2	16.2	NUM
dpc-4159	24	134	)	)	PUNCT
dpc-4159	24	135	33.7	33.7	NUM
dpc-4159	24	136	(	(	PUNCT
dpc-4159	24	137	14.4	14.4	NUM
dpc-4159	24	138	)	)	PUNCT
dpc-4159	24	139	34.8	34.8	NUM
dpc-4159	24	140	(	(	PUNCT
dpc-4159	24	141	17.2	17.2	NUM
dpc-4159	24	142	)	)	PUNCT
dpc-4159	24	143	concomitant	concomitant	ADJ
dpc-4159	24	144	arthritis	arthritis	NOUN
dpc-4159	24	145	,	,	PUNCT
dpc-4159	24	146	%	%	NOUN
dpc-4159	24	147	27.3	27.3	NUM
dpc-4159	24	148	30.8	30.8	NUM
dpc-4159	24	149	28.7	28.7	NUM
dpc-4159	24	150	19.3	19.3	NUM
dpc-4159	24	151	b	b	NOUN
dpc-4159	24	152	psoriasis	psoriasis	NOUN
dpc-4159	24	153	type	type	NOUN
dpc-4159	24	154	,	,	PUNCT
dpc-4159	24	155	%	%	INTJ
dpc-4159	24	156	vulgaris	vulgaris	NOUN
dpc-4159	24	157	84.0	84.0	NUM
dpc-4159	24	158	84.6	84.6	NUM
dpc-4159	24	159	80.9	80.9	NUM
dpc-4159	24	160	86.4	86.4	NUM
dpc-4159	24	161	inverse	inverse	NOUN
dpc-4159	24	162	3.1	3.1	NUM
dpc-4159	24	163	2.5	2.5	NUM
dpc-4159	24	164	0.8	0.8	NUM
dpc-4159	24	165	6.4	6.4	NUM
dpc-4159	24	166	a	a	DET
dpc-4159	24	167	,	,	PUNCT
dpc-4159	24	168	b	b	NOUN
dpc-4159	24	169	,	,	PUNCT
dpc-4159	24	170	c	c	PROPN
dpc-4159	24	171	othersa	othersa	PROPN
dpc-4159	24	172	4.9	4.9	NUM
dpc-4159	24	173	3.4	3.4	NUM
dpc-4159	24	174	7.0	7.0	NUM
dpc-4159	24	175	5.4	5.4	NUM
dpc-4159	24	176	compositeb	compositeb	PROPN
dpc-4159	24	177	8.0	8.0	NUM
dpc-4159	24	178	9.5	9.5	NUM
dpc-4159	24	179	11.3	11.3	NUM
dpc-4159	24	180	1.8	1.8	NUM
dpc-4159	24	181	b	b	NOUN
dpc-4159	24	182	psoriasis	psoriasis	NOUN
dpc-4159	24	183	site	site	NOUN
dpc-4159	24	184	,	,	PUNCT
dpc-4159	24	185	%	%	NOUN
dpc-4159	24	186	typical	typical	ADJ
dpc-4159	24	187	58.8	58.8	NUM
dpc-4159	24	188	58.7	58.7	NUM
dpc-4159	24	189	44.8	44.8	NUM
dpc-4159	24	190	73.6	73.6	NUM
dpc-4159	24	191	a	a	PRON
dpc-4159	24	192	,	,	PUNCT
dpc-4159	24	193	b	b	NOUN
dpc-4159	24	194	,	,	PUNCT
dpc-4159	24	195	c	c	PROPN
dpc-4159	24	196	folds	fold	VERB
dpc-4159	24	197	27.2	27.2	NUM
dpc-4159	24	198	28.8	28.8	NUM
dpc-4159	24	199	35.3	35.3	NUM
dpc-4159	24	200	15.5	15.5	NUM
dpc-4159	24	201	b	b	NOUN
dpc-4159	24	202	,	,	PUNCT
dpc-4159	24	203	c	c	PROPN
dpc-4159	24	204	hands	hand	NOUN
dpc-4159	24	205	and	and	CCONJ
dpc-4159	24	206	feet	foot	NOUN
dpc-4159	24	207	11.7	11.7	NUM
dpc-4159	24	208	10.0	10.0	NUM
dpc-4159	24	209	16.4	16.4	NUM
dpc-4159	24	210	10.0	10.0	NUM
dpc-4159	24	211	others	other	NOUN
dpc-4159	24	212	(	(	PUNCT
dpc-4159	24	213	nails	nail	NOUN
dpc-4159	24	214	,	,	PUNCT
dpc-4159	24	215	scalp	scalp	NOUN
dpc-4159	24	216	,	,	PUNCT
dpc-4159	24	217	genital	genital	ADJ
dpc-4159	24	218	)	)	PUNCT
dpc-4159	24	219	2.3	2.3	NUM
dpc-4159	24	220	2.5	2.5	NUM
dpc-4159	24	221	3.5	3.5	NUM
dpc-4159	24	222	0.9	0.9	NUM
dpc-4159	24	223	number	number	NOUN
dpc-4159	24	224	of	of	ADP
dpc-4159	24	225	previous	previous	ADJ
dpc-4159	24	226	traditional	traditional	ADJ
dpc-4159	24	227	treatments	treatment	NOUN
dpc-4159	24	228	,	,	PUNCT
dpc-4159	24	229	%	%	INTJ
dpc-4159	24	230	none	none	NOUN
dpc-4159	24	231	4.2	4.2	NUM
dpc-4159	24	232	4.0	4.0	NUM
dpc-4159	24	233	1.7	1.7	NUM
dpc-4159	24	234	7.3	7.3	NUM
dpc-4159	24	235	one	one	NUM
dpc-4159	24	236	31.6	31.6	NUM
dpc-4159	24	237	28.9	28.9	NUM
dpc-4159	24	238	29.3	29.3	NUM
dpc-4159	24	239	39.1	39.1	NUM
dpc-4159	24	240	two	two	NUM
dpc-4159	24	241	34.2	34.2	NUM
dpc-4159	24	242	33.3	33.3	NUM
dpc-4159	24	243	33.6	33.6	NUM
dpc-4159	24	244	36.4	36.4	NUM
dpc-4159	24	245	three	three	NUM
dpc-4159	24	246	or	or	CCONJ
dpc-4159	24	247	more	more	ADJ
dpc-4159	24	248	30.0	30.0	NUM
dpc-4159	24	249	33.8	33.8	NUM
dpc-4159	24	250	35.3	35.3	NUM
dpc-4159	24	251	17.3	17.3	NUM
dpc-4159	24	252	number	number	NOUN
dpc-4159	24	253	of	of	ADP
dpc-4159	24	254	previous	previous	ADJ
dpc-4159	24	255	biologic	biologic	NOUN
dpc-4159	24	256	treatments	treatment	NOUN
dpc-4159	24	257	,	,	PUNCT
dpc-4159	24	258	%	%	INTJ
dpc-4159	24	259	(	(	PUNCT
dpc-4159	24	260	n=395	n=395	PROPN
dpc-4159	24	261	)	)	PUNCT
dpc-4159	24	262	(	(	PUNCT
dpc-4159	24	263	n=189	n=189	PROPN
dpc-4159	24	264	)	)	PUNCT
dpc-4159	24	265	(	(	PUNCT
dpc-4159	24	266	n=111	n=111	PROPN
dpc-4159	24	267	)	)	PUNCT
dpc-4159	24	268	(	(	PUNCT
dpc-4159	24	269	n=95	n=95	NOUN
dpc-4159	24	270	)	)	PUNCT
dpc-4159	24	271	none	none	NOUN
dpc-4159	24	272	24.8	24.8	NUM
dpc-4159	24	273	23.8	23.8	NUM
dpc-4159	24	274	26.1	26.1	NUM
dpc-4159	24	275	25.3	25.3	NUM
dpc-4159	24	276	one	one	NUM
dpc-4159	24	277	29.9	29.9	NUM
dpc-4159	24	278	23.3	23.3	NUM
dpc-4159	24	279	24.3	24.3	NUM
dpc-4159	24	280	49.5	49.5	NUM
dpc-4159	24	281	two	two	NUM
dpc-4159	24	282	21.3	21.3	NUM
dpc-4159	24	283	22.2	22.2	NUM
dpc-4159	24	284	25.2	25.2	NUM
dpc-4159	24	285	14.7	14.7	NUM
dpc-4159	24	286	b	b	NUM
dpc-4159	24	287	three	three	NUM
dpc-4159	24	288	or	or	CCONJ
dpc-4159	24	289	more	more	ADJ
dpc-4159	24	290	24.0	24.0	NUM
dpc-4159	24	291	30.7	30.7	NUM
dpc-4159	24	292	24.3	24.3	NUM
dpc-4159	24	293	10.5	10.5	NUM
dpc-4159	24	294	b	b	NOUN
dpc-4159	24	295	median	median	ADJ
dpc-4159	24	296	duration	duration	NOUN
dpc-4159	24	297	of	of	ADP
dpc-4159	24	298	previous	previous	ADJ
dpc-4159	24	299	biologic	biologic	NOUN
dpc-4159	24	300	treatments	treatment	NOUN
dpc-4159	24	301	in	in	ADP
dpc-4159	24	302	months	month	NOUN
dpc-4159	24	303	(	(	PUNCT
dpc-4159	24	304	iqr	iqr	NOUN
dpc-4159	24	305	)	)	PUNCT
dpc-4159	24	306	29.0	29.0	NUM
dpc-4159	24	307	(	(	PUNCT
dpc-4159	24	308	69.5	69.5	NUM
dpc-4159	24	309	)	)	PUNCT
dpc-4159	24	310	35.0	35.0	NUM
dpc-4159	24	311	(	(	PUNCT
dpc-4159	24	312	69.0	69.0	NUM
dpc-4159	24	313	)	)	PUNCT
dpc-4159	24	314	40.0	40.0	NUM
dpc-4159	24	315	(	(	PUNCT
dpc-4159	24	316	60.0	60.0	NUM
dpc-4159	24	317	)	)	PUNCT
dpc-4159	24	318	14.5	14.5	NUM
dpc-4159	24	319	(	(	PUNCT
dpc-4159	24	320	24.0	24.0	NUM
dpc-4159	24	321	)	)	PUNCT
dpc-4159	24	322	mean	mean	PROPN
dpc-4159	24	323	pasi	pasi	NOUN
dpc-4159	24	324	at	at	ADP
dpc-4159	24	325	baseline	baseline	PROPN
dpc-4159	24	326	(	(	PUNCT
dpc-4159	24	327	sd	sd	NOUN
dpc-4159	24	328	)	)	PUNCT
dpc-4159	24	329	12.9	12.9	NUM
dpc-4159	24	330	(	(	PUNCT
dpc-4159	24	331	7.3	7.3	NUM
dpc-4159	24	332	)	)	PUNCT
dpc-4159	24	333	13.5	13.5	NUM
dpc-4159	24	334	(	(	PUNCT
dpc-4159	24	335	7.6	7.6	NUM
dpc-4159	24	336	)	)	PUNCT
dpc-4159	24	337	11.9	11.9	NUM
dpc-4159	24	338	(	(	PUNCT
dpc-4159	24	339	7.1	7.1	NUM
dpc-4159	24	340	)	)	PUNCT
dpc-4159	24	341	12.9	12.9	NUM
dpc-4159	24	342	(	(	PUNCT
dpc-4159	24	343	6.8	6.8	NUM
dpc-4159	24	344	)	)	PUNCT
dpc-4159	24	345	sd	sd	NOUN
dpc-4159	24	346	:	:	PUNCT
dpc-4159	24	347	standard	standard	ADJ
dpc-4159	24	348	deviation	deviation	NOUN
dpc-4159	24	349	;	;	PUNCT
dpc-4159	24	350	iqr	iqr	NOUN
dpc-4159	24	351	:	:	PUNCT
dpc-4159	24	352	interquartile	interquartile	ADJ
dpc-4159	24	353	range	range	NOUN
dpc-4159	24	354	.	.	PUNCT
dpc-4159	25	1	pasi	pasi	NOUN
dpc-4159	25	2	:	:	PUNCT
dpc-4159	25	3	psoriasis	psoriasis	NOUN
dpc-4159	25	4	area	area	NOUN
dpc-4159	25	5	severity	severity	PROPN
dpc-4159	25	6	index	index	NOUN
dpc-4159	25	7	.	.	PUNCT
dpc-4159	26	1	aguttate	aguttate	ADJ
dpc-4159	26	2	,	,	PUNCT
dpc-4159	26	3	pustular	pustular	ADJ
dpc-4159	26	4	,	,	PUNCT
dpc-4159	26	5	or	or	CCONJ
dpc-4159	26	6	erythrodermic	erythrodermic	ADJ
dpc-4159	26	7	psoriasis	psoriasis	NOUN
dpc-4159	26	8	;	;	PUNCT
dpc-4159	26	9	bmore	bmore	NOUN
dpc-4159	26	10	than	than	ADP
dpc-4159	26	11	one	one	NUM
dpc-4159	26	12	type	type	NOUN
dpc-4159	26	13	of	of	ADP
dpc-4159	26	14	psoriasis	psoriasis	NOUN
dpc-4159	26	15	concomitantly	concomitantly	ADV
dpc-4159	26	16	reported	report	VERB
dpc-4159	26	17	.	.	PUNCT
dpc-4159	27	1	*	*	PUNCT
dpc-4159	27	2	chi	chi	ADJ
dpc-4159	27	3	-	-	PUNCT
dpc-4159	27	4	squared	square	VERB
dpc-4159	27	5	test	test	NOUN
dpc-4159	27	6	for	for	ADP
dpc-4159	27	7	categorical	categorical	ADJ
dpc-4159	27	8	variables	variable	NOUN
dpc-4159	27	9	;	;	PUNCT
dpc-4159	27	10	one	one	NUM
dpc-4159	27	11	-	-	PUNCT
dpc-4159	27	12	way	way	NOUN
dpc-4159	27	13	anova	anova	X
dpc-4159	27	14	with	with	ADP
dpc-4159	27	15	sidak	sidak	NOUN
dpc-4159	27	16	corrections	correction	NOUN
dpc-4159	27	17	for	for	ADP
dpc-4159	27	18	continuous	continuous	ADJ
dpc-4159	27	19	ones	one	NOUN
dpc-4159	27	20	.	.	PUNCT
dpc-4159	28	1	a	a	DET
dpc-4159	28	2	:	:	PUNCT
dpc-4159	28	3	p<0.05	p<0.05	NOUN
dpc-4159	28	4	for	for	ADP
dpc-4159	28	5	the	the	DET
dpc-4159	28	6	comparison	comparison	NOUN
dpc-4159	28	7	between	between	ADP
dpc-4159	28	8	patients	patient	NOUN
dpc-4159	28	9	treated	treat	VERB
dpc-4159	28	10	with	with	ADP
dpc-4159	28	11	guselkumab	guselkumab	NOUN
dpc-4159	28	12	and	and	CCONJ
dpc-4159	28	13	patients	patient	NOUN
dpc-4159	28	14	treated	treat	VERB
dpc-4159	28	15	with	with	ADP
dpc-4159	28	16	risankizumab	risankizumab	NOUN
dpc-4159	28	17	;	;	PUNCT
dpc-4159	28	18	b	b	X
dpc-4159	28	19	:	:	PUNCT
dpc-4159	28	20	p<0.05	p<0.05	NOUN
dpc-4159	28	21	for	for	ADP
dpc-4159	28	22	the	the	DET
dpc-4159	28	23	comparison	comparison	NOUN
dpc-4159	28	24	between	between	ADP
dpc-4159	28	25	patients	patient	NOUN
dpc-4159	28	26	treated	treat	VERB
dpc-4159	28	27	with	with	ADP
dpc-4159	28	28	guselkumab	guselkumab	NOUN
dpc-4159	28	29	and	and	CCONJ
dpc-4159	28	30	patients	patient	NOUN
dpc-4159	28	31	treated	treat	VERB
dpc-4159	28	32	with	with	ADP
dpc-4159	28	33	tildrakizumab	tildrakizumab	NOUN
dpc-4159	28	34	;	;	PUNCT
dpc-4159	28	35	c	c	X
dpc-4159	28	36	:	:	PUNCT
dpc-4159	28	37	p<0.05	p<0.05	NOUN
dpc-4159	28	38	for	for	ADP
dpc-4159	28	39	the	the	DET
dpc-4159	28	40	comparison	comparison	NOUN
dpc-4159	28	41	between	between	ADP
dpc-4159	28	42	patients	patient	NOUN
dpc-4159	28	43	treated	treat	VERB
dpc-4159	28	44	with	with	ADP
dpc-4159	28	45	risankizumab	risankizumab	NOUN
dpc-4159	28	46	and	and	CCONJ
dpc-4159	28	47	patients	patient	NOUN
dpc-4159	28	48	treated	treat	VERB
dpc-4159	28	49	with	with	ADP
dpc-4159	28	50	tildrakizumab	tildrakizumab	NOUN
dpc-4159	28	51	.	.	PUNCT
dpc-4159	29	1	all	all	DET
dpc-4159	29	2	p	p	NOUN
dpc-4159	29	3	-	-	PUNCT
dpc-4159	29	4	values	value	NOUN
dpc-4159	29	5	that	that	PRON
dpc-4159	29	6	are	be	AUX
dpc-4159	29	7	not	not	PART
dpc-4159	29	8	indicated	indicate	VERB
dpc-4159	29	9	were	be	AUX
dpc-4159	29	10	≥0.05	≥0.05	ADJ
dpc-4159	29	11	.	.	PUNCT
dpc-4159	30	1	research	research	NOUN
dpc-4159	30	2	letter	letter	NOUN
dpc-4159	31	1	|	|	ADV
dpc-4159	31	2	dermatol	dermatol	ADJ
dpc-4159	31	3	pract	pract	NOUN
dpc-4159	31	4	concept	concept	NOUN
dpc-4159	31	5	.	.	PUNCT
dpc-4159	32	1	2024;14(3):e2024179	2024;14(3):e2024179	NUM
dpc-4159	32	2	3	3	NUM
dpc-4159	32	3	overall	overall	NOUN
dpc-4159	32	4	,	,	PUNCT
dpc-4159	32	5	63.9	63.9	NUM
dpc-4159	32	6	%	%	NOUN
dpc-4159	32	7	of	of	ADP
dpc-4159	32	8	the	the	DET
dpc-4159	32	9	patients	patient	NOUN
dpc-4159	32	10	had	have	VERB
dpc-4159	32	11	at	at	ADV
dpc-4159	32	12	least	least	ADV
dpc-4159	32	13	one	one	NUM
dpc-4159	32	14	comorbidity	comorbidity	NOUN
dpc-4159	32	15	,	,	PUNCT
dpc-4159	32	16	including	include	VERB
dpc-4159	32	17	infectious	infectious	ADJ
dpc-4159	32	18	,	,	PUNCT
dpc-4159	32	19	cardiometabolic	cardiometabolic	NOUN
dpc-4159	32	20	and	and	CCONJ
dpc-4159	32	21	autoimmune	autoimmune	ADJ
dpc-4159	32	22	diseases	disease	NOUN
dpc-4159	32	23	or	or	CCONJ
dpc-4159	32	24	cancer	cancer	NOUN
dpc-4159	32	25	-	-	PUNCT
dpc-4159	32	26	positive	positive	ADJ
dpc-4159	32	27	history	history	NOUN
dpc-4159	32	28	;	;	PUNCT
dpc-4159	32	29	27.3	27.3	NUM
dpc-4159	32	30	%	%	NOUN
dpc-4159	32	31	had	have	VERB
dpc-4159	32	32	concomitant	concomitant	ADJ
dpc-4159	32	33	psoriatic	psoriatic	ADJ
dpc-4159	32	34	arthritis	arthritis	NOUN
dpc-4159	32	35	.	.	PUNCT
dpc-4159	33	1	at	at	ADP
dpc-4159	33	2	baseline	baseline	NOUN
dpc-4159	33	3	,	,	PUNCT
dpc-4159	33	4	the	the	DET
dpc-4159	33	5	mean	mean	ADJ
dpc-4159	33	6	pasi	pasi	NOUN
dpc-4159	33	7	was	be	AUX
dpc-4159	33	8	12.9	12.9	NUM
dpc-4159	33	9	±7.3	±7.3	NOUN
dpc-4159	33	10	,	,	PUNCT
dpc-4159	33	11	without	without	ADP
dpc-4159	33	12	differences	difference	NOUN
dpc-4159	33	13	among	among	ADP
dpc-4159	33	14	treatment	treatment	NOUN
dpc-4159	33	15	groups	group	NOUN
dpc-4159	33	16	.	.	PUNCT
dpc-4159	34	1	with	with	ADP
dpc-4159	34	2	reference	reference	NOUN
dpc-4159	34	3	to	to	ADP
dpc-4159	34	4	previous	previous	ADJ
dpc-4159	34	5	systemic	systemic	ADJ
dpc-4159	34	6	treatments	treatment	NOUN
dpc-4159	34	7	for	for	ADP
dpc-4159	34	8	psoriasis	psoriasis	NOUN
dpc-4159	34	9	,	,	PUNCT
dpc-4159	34	10	95.8	95.8	NUM
dpc-4159	34	11	%	%	NOUN
dpc-4159	34	12	of	of	ADP
dpc-4159	34	13	patients	patient	NOUN
dpc-4159	34	14	had	have	AUX
dpc-4159	34	15	previously	previously	ADV
dpc-4159	34	16	been	be	AUX
dpc-4159	34	17	treated	treat	VERB
dpc-4159	34	18	with	with	ADP
dpc-4159	34	19	at	at	ADV
dpc-4159	34	20	least	least	ADV
dpc-4159	34	21	one	one	NUM
dpc-4159	34	22	traditional	traditional	ADJ
dpc-4159	34	23	drug	drug	NOUN
dpc-4159	34	24	and	and	CCONJ
dpc-4159	34	25	75.2	75.2	NUM
dpc-4159	34	26	%	%	NOUN
dpc-4159	34	27	were	be	AUX
dpc-4159	34	28	biologic	biologic	NOUN
dpc-4159	34	29	-	-	PUNCT
dpc-4159	34	30	experienced	experienced	ADJ
dpc-4159	34	31	.	.	PUNCT
dpc-4159	35	1	after	after	ADP
dpc-4159	35	2	12	12	NUM
dpc-4159	35	3	weeks	week	NOUN
dpc-4159	35	4	of	of	ADP
dpc-4159	35	5	treatment	treatment	NOUN
dpc-4159	35	6	,	,	PUNCT
dpc-4159	35	7	mean	mean	VERB
dpc-4159	35	8	pasi	pasi	NOUN
dpc-4159	35	9	score	score	NOUN
dpc-4159	35	10	decreased	decrease	VERB
dpc-4159	35	11	by	by	ADP
dpc-4159	35	12	almost	almost	ADV
dpc-4159	35	13	80	80	NUM
dpc-4159	35	14	%	%	NOUN
dpc-4159	35	15	from	from	ADP
dpc-4159	35	16	baseline	baseline	NOUN
dpc-4159	35	17	in	in	ADP
dpc-4159	35	18	the	the	DET
dpc-4159	35	19	entire	entire	ADJ
dpc-4159	35	20	study	study	NOUN
dpc-4159	35	21	population	population	NOUN
dpc-4159	35	22	and	and	CCONJ
dpc-4159	35	23	nearly	nearly	ADV
dpc-4159	35	24	half	half	NOUN
dpc-4159	35	25	of	of	ADP
dpc-4159	35	26	the	the	DET
dpc-4159	35	27	subjects	subject	NOUN
dpc-4159	35	28	achieved	achieve	VERB
dpc-4159	35	29	pasi90	pasi90	NOUN
dpc-4159	35	30	(	(	PUNCT
dpc-4159	35	31	table	table	NOUN
dpc-4159	35	32	2	2	NUM
dpc-4159	35	33	)	)	PUNCT
dpc-4159	35	34	.	.	PUNCT
dpc-4159	36	1	a	a	DET
dpc-4159	36	2	complete	complete	ADJ
dpc-4159	36	3	clearance	clearance	NOUN
dpc-4159	36	4	was	be	AUX
dpc-4159	36	5	reached	reach	VERB
dpc-4159	36	6	by	by	ADP
dpc-4159	36	7	more	more	ADJ
dpc-4159	36	8	than	than	ADP
dpc-4159	36	9	one	one	NUM
dpc-4159	36	10	third	third	NOUN
dpc-4159	36	11	of	of	ADP
dpc-4159	36	12	the	the	DET
dpc-4159	36	13	study	study	NOUN
dpc-4159	36	14	patients	patient	NOUN
dpc-4159	36	15	at	at	ADP
dpc-4159	36	16	this	this	DET
dpc-4159	36	17	time	time	NOUN
dpc-4159	36	18	point	point	NOUN
dpc-4159	36	19	.	.	PUNCT
dpc-4159	37	1	it	it	PRON
dpc-4159	37	2	should	should	AUX
dpc-4159	37	3	be	be	AUX
dpc-4159	37	4	noted	note	VERB
dpc-4159	37	5	that	that	SCONJ
dpc-4159	37	6	in	in	ADP
dpc-4159	37	7	the	the	DET
dpc-4159	37	8	early	early	ADJ
dpc-4159	37	9	stages	stage	NOUN
dpc-4159	37	10	of	of	ADP
dpc-4159	37	11	treatment	treatment	NOUN
dpc-4159	37	12	,	,	PUNCT
dpc-4159	37	13	a	a	DET
dpc-4159	37	14	difference	difference	NOUN
dpc-4159	37	15	was	be	AUX
dpc-4159	37	16	observed	observe	VERB
dpc-4159	37	17	among	among	ADP
dpc-4159	37	18	the	the	DET
dpc-4159	37	19	three	three	NUM
dpc-4159	37	20	molecules	molecule	NOUN
dpc-4159	37	21	.	.	PUNCT
dpc-4159	38	1	in	in	ADP
dpc-4159	38	2	fact	fact	NOUN
dpc-4159	38	3	,	,	PUNCT
dpc-4159	38	4	risankizumab	risankizumab	PROPN
dpc-4159	38	5	was	be	AUX
dpc-4159	38	6	significantly	significantly	ADV
dpc-4159	38	7	more	more	ADV
dpc-4159	38	8	effective	effective	ADJ
dpc-4159	38	9	than	than	ADP
dpc-4159	38	10	the	the	DET
dpc-4159	38	11	other	other	ADJ
dpc-4159	38	12	two	two	NUM
dpc-4159	38	13	molecules	molecule	NOUN
dpc-4159	38	14	after	after	SCONJ
dpc-4159	38	15	a	a	DET
dpc-4159	38	16	12	12	NUM
dpc-4159	38	17	-	-	PUNCT
dpc-4159	38	18	week	week	NOUN
dpc-4159	38	19	treatment	treatment	NOUN
dpc-4159	38	20	duration	duration	NOUN
dpc-4159	38	21	and	and	CCONJ
dpc-4159	38	22	guselkumab	guselkumab	NOUN
dpc-4159	38	23	was	be	AUX
dpc-4159	38	24	more	more	ADV
dpc-4159	38	25	effective	effective	ADJ
dpc-4159	38	26	than	than	ADP
dpc-4159	38	27	tildrakizumab	tildrakizumab	NOUN
dpc-4159	38	28	.	.	PUNCT
dpc-4159	39	1	after	after	ADP
dpc-4159	39	2	28	28	NUM
dpc-4159	39	3	weeks	week	NOUN
dpc-4159	39	4	,	,	PUNCT
dpc-4159	39	5	clinical	clinical	ADJ
dpc-4159	39	6	improvement	improvement	NOUN
dpc-4159	39	7	was	be	AUX
dpc-4159	39	8	further	far	ADV
dpc-4159	39	9	increased	increase	VERB
dpc-4159	39	10	,	,	PUNCT
dpc-4159	39	11	with	with	ADP
dpc-4159	39	12	a	a	DET
dpc-4159	39	13	mean	mean	ADJ
dpc-4159	39	14	pasi	pasi	NOUN
dpc-4159	39	15	reduction	reduction	NOUN
dpc-4159	39	16	of	of	ADP
dpc-4159	39	17	86	86	NUM
dpc-4159	39	18	%	%	NOUN
dpc-4159	39	19	compared	compare	VERB
dpc-4159	39	20	with	with	ADP
dpc-4159	39	21	the	the	DET
dpc-4159	39	22	baseline	baseline	NOUN
dpc-4159	39	23	.	.	PUNCT
dpc-4159	40	1	mean	mean	ADJ
dpc-4159	40	2	pasi	pasi	PROPN
dpc-4159	40	3	was	be	AUX
dpc-4159	40	4	1.5	1.5	NUM
dpc-4159	40	5	±3.3	±3.3	NOUN
dpc-4159	40	6	in	in	ADP
dpc-4159	40	7	the	the	DET
dpc-4159	40	8	study	study	NOUN
dpc-4159	40	9	population	population	NOUN
dpc-4159	40	10	considered	consider	VERB
dpc-4159	40	11	as	as	ADP
dpc-4159	40	12	a	a	DET
dpc-4159	40	13	whole	whole	NOUN
dpc-4159	40	14	.	.	PUNCT
dpc-4159	41	1	nearly	nearly	ADV
dpc-4159	41	2	60	60	NUM
dpc-4159	41	3	%	%	NOUN
dpc-4159	41	4	of	of	ADP
dpc-4159	41	5	patients	patient	NOUN
dpc-4159	41	6	achieved	achieve	VERB
dpc-4159	41	7	complete	complete	ADJ
dpc-4159	41	8	clearance	clearance	NOUN
dpc-4159	41	9	.	.	PUNCT
dpc-4159	42	1	unlike	unlike	ADP
dpc-4159	42	2	the	the	DET
dpc-4159	42	3	first	first	ADJ
dpc-4159	42	4	weeks	week	NOUN
dpc-4159	42	5	of	of	ADP
dpc-4159	42	6	treatment	treatment	NOUN
dpc-4159	42	7	,	,	PUNCT
dpc-4159	42	8	no	no	DET
dpc-4159	42	9	significant	significant	ADJ
dpc-4159	42	10	differences	difference	NOUN
dpc-4159	42	11	were	be	AUX
dpc-4159	42	12	found	find	VERB
dpc-4159	42	13	with	with	ADP
dpc-4159	42	14	respect	respect	NOUN
dpc-4159	42	15	to	to	ADP
dpc-4159	42	16	the	the	DET
dpc-4159	42	17	performance	performance	NOUN
dpc-4159	42	18	of	of	ADP
dpc-4159	42	19	the	the	DET
dpc-4159	42	20	three	three	NUM
dpc-4159	42	21	molecules	molecule	NOUN
dpc-4159	42	22	at	at	ADP
dpc-4159	42	23	the	the	DET
dpc-4159	42	24	28	28	NUM
dpc-4159	42	25	-	-	PUNCT
dpc-4159	42	26	week	week	NOUN
dpc-4159	42	27	control	control	NOUN
dpc-4159	42	28	.	.	PUNCT
dpc-4159	43	1	gender	gender	NOUN
dpc-4159	43	2	,	,	PUNCT
dpc-4159	43	3	age	age	NOUN
dpc-4159	43	4	,	,	PUNCT
dpc-4159	43	5	bmi	bmi	NOUN
dpc-4159	43	6	,	,	PUNCT
dpc-4159	43	7	disease	disease	NOUN
dpc-4159	43	8	duration	duration	NOUN
dpc-4159	43	9	,	,	PUNCT
dpc-4159	43	10	concomitant	concomitant	ADJ
dpc-4159	43	11	psoriatic	psoriatic	ADJ
dpc-4159	43	12	arthritis	arthritis	NOUN
dpc-4159	43	13	,	,	PUNCT
dpc-4159	43	14	involvement	involvement	NOUN
dpc-4159	43	15	of	of	ADP
dpc-4159	43	16	particular	particular	ADJ
dpc-4159	43	17	anatomical	anatomical	ADJ
dpc-4159	43	18	districts	district	NOUN
dpc-4159	43	19	,	,	PUNCT
dpc-4159	43	20	number	number	NOUN
dpc-4159	43	21	of	of	ADP
dpc-4159	43	22	previous	previous	ADJ
dpc-4159	43	23	traditional	traditional	ADJ
dpc-4159	43	24	treatments	treatment	NOUN
dpc-4159	43	25	and	and	CCONJ
dpc-4159	43	26	duration	duration	NOUN
dpc-4159	43	27	of	of	ADP
dpc-4159	43	28	previous	previous	ADJ
dpc-4159	43	29	biologic	biologic	NOUN
dpc-4159	43	30	treatments	treatment	NOUN
dpc-4159	43	31	did	do	AUX
dpc-4159	43	32	not	not	PART
dpc-4159	43	33	correlate	correlate	VERB
dpc-4159	43	34	with	with	ADP
dpc-4159	43	35	psoriasis	psoriasis	NOUN
dpc-4159	43	36	improvement	improvement	NOUN
dpc-4159	43	37	.	.	PUNCT
dpc-4159	44	1	therefore	therefore	ADV
dpc-4159	44	2	,	,	PUNCT
dpc-4159	44	3	involvement	involvement	NOUN
dpc-4159	44	4	of	of	ADP
dpc-4159	44	5	critical	critical	ADJ
dpc-4159	44	6	and/	and/	NOUN
dpc-4159	44	7	or	or	CCONJ
dpc-4159	44	8	difficult	difficult	ADJ
dpc-4159	44	9	-	-	PUNCT
dpc-4159	44	10	to	to	ADP
dpc-4159	44	11	-	-	PUNCT
dpc-4159	44	12	treat	treat	VERB
dpc-4159	44	13	skin	skin	NOUN
dpc-4159	44	14	areas	area	NOUN
dpc-4159	44	15	,	,	PUNCT
dpc-4159	44	16	including	include	VERB
dpc-4159	44	17	face	face	NOUN
dpc-4159	44	18	,	,	PUNCT
dpc-4159	44	19	palms	palm	NOUN
dpc-4159	44	20	,	,	PUNCT
dpc-4159	44	21	soles	sol	NOUN
dpc-4159	44	22	,	,	PUNCT
dpc-4159	44	23	scalp	scalp	NOUN
dpc-4159	44	24	and	and	CCONJ
dpc-4159	44	25	genitals	genital	NOUN
dpc-4159	44	26	,	,	PUNCT
dpc-4159	44	27	which	which	PRON
dpc-4159	44	28	are	be	AUX
dpc-4159	44	29	characterized	characterize	VERB
dpc-4159	44	30	by	by	ADP
dpc-4159	44	31	a	a	DET
dpc-4159	44	32	high	high	ADJ
dpc-4159	44	33	impact	impact	NOUN
dpc-4159	44	34	on	on	ADP
dpc-4159	44	35	sufferers	sufferer	NOUN
dpc-4159	44	36	’	'	PUNCT
dpc-4159	44	37	quality	quality	NOUN
dpc-4159	44	38	of	of	ADP
dpc-4159	44	39	life	life	NOUN
dpc-4159	44	40	and	and	CCONJ
dpc-4159	44	41	functionality	functionality	NOUN
dpc-4159	44	42	,	,	PUNCT
dpc-4159	44	43	overweight	overweight	NOUN
dpc-4159	44	44	or	or	CCONJ
dpc-4159	44	45	obesity	obesity	NOUN
dpc-4159	44	46	,	,	PUNCT
dpc-4159	44	47	which	which	PRON
dpc-4159	44	48	are	be	AUX
dpc-4159	44	49	common	common	ADJ
dpc-4159	44	50	among	among	ADP
dpc-4159	44	51	psoriatic	psoriatic	ADJ
dpc-4159	44	52	patients	patient	NOUN
dpc-4159	44	53	,	,	PUNCT
dpc-4159	44	54	or	or	CCONJ
dpc-4159	44	55	table	table	NOUN
dpc-4159	44	56	2	2	NUM
dpc-4159	44	57	.	.	NUM
dpc-4159	44	58	selected	select	VERB
dpc-4159	44	59	clinical	clinical	ADJ
dpc-4159	44	60	characteristic	characteristic	NOUN
dpc-4159	44	61	of	of	ADP
dpc-4159	44	62	the	the	DET
dpc-4159	44	63	sample	sample	NOUN
dpc-4159	44	64	,	,	PUNCT
dpc-4159	44	65	and	and	CCONJ
dpc-4159	44	66	outcomes	outcome	NOUN
dpc-4159	44	67	,	,	PUNCT
dpc-4159	44	68	overall	overall	ADV
dpc-4159	44	69	and	and	CCONJ
dpc-4159	44	70	by	by	ADP
dpc-4159	44	71	type	type	NOUN
dpc-4159	44	72	of	of	ADP
dpc-4159	44	73	anti	anti	ADJ
dpc-4159	44	74	-	-	ADJ
dpc-4159	44	75	il23	il23	PROPN
dpc-4159	44	76	.	.	PUNCT
dpc-4159	45	1	variables	variable	NOUN
dpc-4159	45	2	overall	overall	ADJ
dpc-4159	45	3	sample	sample	NOUN
dpc-4159	45	4	(	(	PUNCT
dpc-4159	45	5	n=427	n=427	NOUN
dpc-4159	45	6	)	)	PUNCT
dpc-4159	45	7	guselkumab	guselkumab	NOUN
dpc-4159	45	8	(	(	PUNCT
dpc-4159	45	9	n=201	n=201	NOUN
dpc-4159	45	10	)	)	PUNCT
dpc-4159	45	11	risankizumab	risankizumab	NOUN
dpc-4159	45	12	(	(	PUNCT
dpc-4159	45	13	n=116	n=116	NUM
dpc-4159	45	14	)	)	PUNCT
dpc-4159	45	15	tildrakizumab	tildrakizumab	NOUN
dpc-4159	45	16	(	(	PUNCT
dpc-4159	45	17	n=110	n=110	PROPN
dpc-4159	45	18	)	)	PUNCT
dpc-4159	46	1	p	p	X
dpc-4159	46	2	*	*	PUNCT
dpc-4159	46	3	mean	mean	ADJ
dpc-4159	46	4	duration	duration	NOUN
dpc-4159	46	5	of	of	ADP
dpc-4159	46	6	anti	anti	ADJ
dpc-4159	46	7	-	-	ADJ
dpc-4159	46	8	il	il	ADJ
dpc-4159	46	9	23	23	NUM
dpc-4159	46	10	treatment	treatment	NOUN
dpc-4159	46	11	in	in	ADP
dpc-4159	46	12	months	month	NOUN
dpc-4159	46	13	(	(	PUNCT
dpc-4159	46	14	sd)a	sd)a	NOUN
dpc-4159	46	15	18.9	18.9	NUM
dpc-4159	46	16	(	(	PUNCT
dpc-4159	46	17	10.8	10.8	NUM
dpc-4159	46	18	)	)	PUNCT
dpc-4159	46	19	22.2	22.2	NUM
dpc-4159	46	20	(	(	PUNCT
dpc-4159	46	21	11.7	11.7	NUM
dpc-4159	46	22	)	)	PUNCT
dpc-4159	46	23	15.9	15.9	NUM
dpc-4159	46	24	(	(	PUNCT
dpc-4159	46	25	7.5	7.5	NUM
dpc-4159	46	26	)	)	PUNCT
dpc-4159	46	27	15.8	15.8	NUM
dpc-4159	46	28	(	(	PUNCT
dpc-4159	46	29	10.4	10.4	NUM
dpc-4159	46	30	)	)	PUNCT
dpc-4159	46	31	a	a	PRON
dpc-4159	46	32	,	,	PUNCT
dpc-4159	46	33	b	b	PROPN
dpc-4159	46	34	drug	drug	NOUN
dpc-4159	46	35	survival	survival	NOUN
dpc-4159	46	36	,	,	PUNCT
dpc-4159	47	1	%	%	NOUN
dpc-4159	47	2	94.6	94.6	NUM
dpc-4159	47	3	95.0	95.0	NUM
dpc-4159	47	4	96.6	96.6	NUM
dpc-4159	47	5	91.7	91.7	NUM
dpc-4159	47	6	mean	mean	NOUN
dpc-4159	47	7	pasi	pasi	NOUN
dpc-4159	47	8	at	at	ADP
dpc-4159	47	9	baseline	baseline	PROPN
dpc-4159	47	10	(	(	PUNCT
dpc-4159	47	11	sd	sd	NOUN
dpc-4159	47	12	)	)	PUNCT
dpc-4159	47	13	12.9	12.9	NUM
dpc-4159	47	14	(	(	PUNCT
dpc-4159	47	15	7.3	7.3	NUM
dpc-4159	47	16	)	)	PUNCT
dpc-4159	47	17	13.5	13.5	NUM
dpc-4159	47	18	(	(	PUNCT
dpc-4159	47	19	7.6	7.6	NUM
dpc-4159	47	20	)	)	PUNCT
dpc-4159	47	21	11.9	11.9	NUM
dpc-4159	47	22	(	(	PUNCT
dpc-4159	47	23	7.1	7.1	NUM
dpc-4159	47	24	)	)	PUNCT
dpc-4159	47	25	12.9	12.9	NUM
dpc-4159	47	26	(	(	PUNCT
dpc-4159	47	27	6.8	6.8	NUM
dpc-4159	47	28	)	)	PUNCT
dpc-4159	47	29	mean	mean	ADJ
dpc-4159	47	30	pasi	pasi	NOUN
dpc-4159	47	31	at	at	ADP
dpc-4159	47	32	week	week	NOUN
dpc-4159	47	33	12	12	NUM
dpc-4159	47	34	(	(	PUNCT
dpc-4159	47	35	sd	sd	NOUN
dpc-4159	47	36	)	)	PUNCT
dpc-4159	47	37	2.8	2.8	NUM
dpc-4159	47	38	(	(	PUNCT
dpc-4159	47	39	3.4	3.4	NUM
dpc-4159	47	40	)	)	PUNCT
dpc-4159	47	41	2.2	2.2	NUM
dpc-4159	47	42	(	(	PUNCT
dpc-4159	47	43	2.1	2.1	NUM
dpc-4159	47	44	)	)	PUNCT
dpc-4159	47	45	1.5	1.5	NUM
dpc-4159	47	46	(	(	PUNCT
dpc-4159	47	47	2.7	2.7	NUM
dpc-4159	47	48	)	)	PUNCT
dpc-4159	47	49	4.1	4.1	NUM
dpc-4159	47	50	(	(	PUNCT
dpc-4159	47	51	4.5	4.5	NUM
dpc-4159	47	52	)	)	PUNCT
dpc-4159	47	53	mean	mean	VERB
dpc-4159	47	54	pasi	pasi	NOUN
dpc-4159	47	55	%	%	NOUN
dpc-4159	47	56	reduction	reduction	NOUN
dpc-4159	47	57	between	between	ADP
dpc-4159	47	58	baseline	baseline	NOUN
dpc-4159	47	59	and	and	CCONJ
dpc-4159	47	60	week	week	NOUN
dpc-4159	47	61	12	12	NUM
dpc-4159	47	62	,	,	PUNCT
dpc-4159	47	63	(	(	PUNCT
dpc-4159	47	64	sd	sd	NOUN
dpc-4159	47	65	)	)	PUNCT
dpc-4159	47	66	77.8	77.8	NUM
dpc-4159	47	67	(	(	PUNCT
dpc-4159	47	68	25.9	25.9	NUM
dpc-4159	47	69	)	)	PUNCT
dpc-4159	47	70	82.2	82.2	NUM
dpc-4159	47	71	(	(	PUNCT
dpc-4159	47	72	18.7	18.7	NUM
dpc-4159	47	73	)	)	PUNCT
dpc-4159	47	74	89.8	89.8	NUM
dpc-4159	47	75	(	(	PUNCT
dpc-4159	47	76	20.5	20.5	NUM
dpc-4159	47	77	)	)	PUNCT
dpc-4159	47	78	67.4	67.4	NUM
dpc-4159	47	79	(	(	PUNCT
dpc-4159	47	80	31.4	31.4	NUM
dpc-4159	47	81	)	)	PUNCT
dpc-4159	47	82	b	b	NOUN
dpc-4159	47	83	,	,	PUNCT
dpc-4159	47	84	c	c	PROPN
dpc-4159	47	85	baseline	baseline	NOUN
dpc-4159	47	86	-	-	PUNCT
dpc-4159	47	87	week	week	NOUN
dpc-4159	47	88	12	12	NUM
dpc-4159	47	89	pasi	pasi	NOUN
dpc-4159	47	90	reduction	reduction	NOUN
dpc-4159	47	91	≥75	≥75	NOUN
dpc-4159	47	92	%	%	NOUN
dpc-4159	47	93	,	,	PUNCT
dpc-4159	48	1	%	%	NOUN
dpc-4159	48	2	63.3	63.3	NUM
dpc-4159	48	3	67.3	67.3	NUM
dpc-4159	48	4	86.1	86.1	NUM
dpc-4159	48	5	48.8	48.8	NUM
dpc-4159	48	6	a	a	DET
dpc-4159	48	7	,	,	PUNCT
dpc-4159	48	8	b	b	NOUN
dpc-4159	48	9	,	,	PUNCT
dpc-4159	48	10	c	c	PROPN
dpc-4159	48	11	baseline	baseline	NOUN
dpc-4159	48	12	-	-	PUNCT
dpc-4159	48	13	week	week	NOUN
dpc-4159	48	14	12	12	NUM
dpc-4159	48	15	pasi	pasi	NOUN
dpc-4159	48	16	reduction	reduction	NOUN
dpc-4159	48	17	≥90	≥90	NUM
dpc-4159	48	18	%	%	NOUN
dpc-4159	48	19	,	,	PUNCT
dpc-4159	48	20	%	%	NOUN
dpc-4159	48	21	45.0	45.0	NUM
dpc-4159	48	22	45.8	45.8	NUM
dpc-4159	48	23	72.2	72.2	NUM
dpc-4159	48	24	32.6	32.6	NUM
dpc-4159	48	25	a	a	PRON
dpc-4159	48	26	,	,	PUNCT
dpc-4159	48	27	c	c	PROPN
dpc-4159	48	28	baseline	baseline	NOUN
dpc-4159	48	29	-	-	PUNCT
dpc-4159	48	30	week	week	NOUN
dpc-4159	48	31	12	12	NUM
dpc-4159	48	32	pasi	pasi	NOUN
dpc-4159	48	33	100	100	NUM
dpc-4159	48	34	%	%	NOUN
dpc-4159	48	35	decrease	decrease	NOUN
dpc-4159	48	36	,	,	PUNCT
dpc-4159	48	37	%	%	NOUN
dpc-4159	48	38	34.1	34.1	NUM
dpc-4159	48	39	30.8	30.8	NUM
dpc-4159	48	40	69.4	69.4	NUM
dpc-4159	48	41	23.3	23.3	NUM
dpc-4159	48	42	a	a	DET
dpc-4159	48	43	,	,	PUNCT
dpc-4159	48	44	b	b	NOUN
dpc-4159	48	45	,	,	PUNCT
dpc-4159	48	46	c	c	NOUN
dpc-4159	48	47	mean	mean	NOUN
dpc-4159	48	48	pasi	pasi	NOUN
dpc-4159	48	49	at	at	ADP
dpc-4159	48	50	week	week	NOUN
dpc-4159	48	51	16	16	NUM
dpc-4159	48	52	(	(	PUNCT
dpc-4159	48	53	sd	sd	NOUN
dpc-4159	48	54	)	)	PUNCT
dpc-4159	48	55	1.8	1.8	NUM
dpc-4159	48	56	(	(	PUNCT
dpc-4159	48	57	3.0	3.0	NUM
dpc-4159	48	58	)	)	PUNCT
dpc-4159	48	59	1.6	1.6	NUM
dpc-4159	48	60	(	(	PUNCT
dpc-4159	48	61	2.4	2.4	NUM
dpc-4159	48	62	)	)	PUNCT
dpc-4159	48	63	1.2	1.2	NUM
dpc-4159	48	64	(	(	PUNCT
dpc-4159	48	65	2.5	2.5	NUM
dpc-4159	48	66	)	)	PUNCT
dpc-4159	48	67	4.4	4.4	NUM
dpc-4159	48	68	(	(	PUNCT
dpc-4159	48	69	5.1	5.1	NUM
dpc-4159	48	70	)	)	PUNCT
dpc-4159	48	71	b	b	NOUN
dpc-4159	48	72	,	,	PUNCT
dpc-4159	48	73	c	c	NOUN
dpc-4159	48	74	mean	mean	VERB
dpc-4159	48	75	pasi	pasi	NOUN
dpc-4159	48	76	%	%	NOUN
dpc-4159	48	77	reduction	reduction	NOUN
dpc-4159	48	78	between	between	ADP
dpc-4159	48	79	baseline	baseline	NOUN
dpc-4159	48	80	and	and	CCONJ
dpc-4159	48	81	week	week	NOUN
dpc-4159	48	82	16	16	NUM
dpc-4159	48	83	,	,	PUNCT
dpc-4159	48	84	(	(	PUNCT
dpc-4159	48	85	sd	sd	NOUN
dpc-4159	48	86	)	)	PUNCT
dpc-4159	48	87	81.9	81.9	NUM
dpc-4159	48	88	(	(	PUNCT
dpc-4159	48	89	39.5	39.5	NUM
dpc-4159	48	90	)	)	PUNCT
dpc-4159	48	91	82.6	82.6	NUM
dpc-4159	48	92	(	(	PUNCT
dpc-4159	48	93	41.3	41.3	NUM
dpc-4159	48	94	)	)	PUNCT
dpc-4159	48	95	86.6	86.6	NUM
dpc-4159	48	96	(	(	PUNCT
dpc-4159	48	97	30.4	30.4	NUM
dpc-4159	48	98	)	)	PUNCT
dpc-4159	48	99	64.5	64.5	NUM
dpc-4159	49	1	(	(	PUNCT
dpc-4159	49	2	51.0	51.0	NUM
dpc-4159	49	3	)	)	PUNCT
dpc-4159	49	4	baseline	baseline	NOUN
dpc-4159	49	5	-	-	PUNCT
dpc-4159	49	6	week	week	NOUN
dpc-4159	49	7	16	16	NUM
dpc-4159	49	8	pasi	pasi	NOUN
dpc-4159	49	9	90	90	NUM
dpc-4159	49	10	%	%	NOUN
dpc-4159	49	11	decrease	decrease	NOUN
dpc-4159	49	12	,	,	PUNCT
dpc-4159	49	13	%	%	NOUN
dpc-4159	49	14	64.7	64.7	NUM
dpc-4159	49	15	64.9	64.9	NUM
dpc-4159	49	16	75.0	75.0	NUM
dpc-4159	49	17	33.3	33.3	NUM
dpc-4159	49	18	b	b	NOUN
dpc-4159	49	19	,	,	PUNCT
dpc-4159	49	20	c	c	PROPN
dpc-4159	49	21	baseline	baseline	NOUN
dpc-4159	49	22	-	-	PUNCT
dpc-4159	49	23	week	week	NOUN
dpc-4159	49	24	16	16	NUM
dpc-4159	49	25	pasi	pasi	NOUN
dpc-4159	49	26	100	100	NUM
dpc-4159	49	27	%	%	NOUN
dpc-4159	49	28	decrease	decrease	NOUN
dpc-4159	49	29	,	,	PUNCT
dpc-4159	49	30	%	%	NOUN
dpc-4159	49	31	47.4	47.4	NUM
dpc-4159	49	32	39.2	39.2	NUM
dpc-4159	49	33	68.2	68.2	NUM
dpc-4159	49	34	26.7	26.7	NUM
dpc-4159	49	35	a	a	PRON
dpc-4159	49	36	,	,	PUNCT
dpc-4159	49	37	c	c	NOUN
dpc-4159	49	38	mean	mean	NOUN
dpc-4159	49	39	pasi	pasi	NOUN
dpc-4159	49	40	at	at	ADP
dpc-4159	49	41	week	week	NOUN
dpc-4159	49	42	28	28	NUM
dpc-4159	49	43	(	(	PUNCT
dpc-4159	49	44	sd	sd	NOUN
dpc-4159	49	45	)	)	PUNCT
dpc-4159	49	46	1.5	1.5	NUM
dpc-4159	49	47	(	(	PUNCT
dpc-4159	49	48	3.3	3.3	NUM
dpc-4159	49	49	)	)	PUNCT
dpc-4159	49	50	1.2	1.2	NUM
dpc-4159	49	51	(	(	PUNCT
dpc-4159	49	52	2.9	2.9	NUM
dpc-4159	49	53	)	)	PUNCT
dpc-4159	49	54	1.5	1.5	NUM
dpc-4159	49	55	(	(	PUNCT
dpc-4159	49	56	2.8	2.8	NUM
dpc-4159	49	57	)	)	PUNCT
dpc-4159	49	58	1.9	1.9	NUM
dpc-4159	49	59	(	(	PUNCT
dpc-4159	49	60	4.0	4.0	NUM
dpc-4159	49	61	)	)	PUNCT
dpc-4159	49	62	mean	mean	VERB
dpc-4159	49	63	pasi	pasi	NOUN
dpc-4159	49	64	%	%	NOUN
dpc-4159	49	65	reduction	reduction	NOUN
dpc-4159	49	66	between	between	ADP
dpc-4159	49	67	baseline	baseline	NOUN
dpc-4159	49	68	and	and	CCONJ
dpc-4159	49	69	week	week	NOUN
dpc-4159	49	70	28	28	NUM
dpc-4159	49	71	,	,	PUNCT
dpc-4159	49	72	(	(	PUNCT
dpc-4159	49	73	sd	sd	NOUN
dpc-4159	49	74	)	)	PUNCT
dpc-4159	49	75	86.0	86.0	NUM
dpc-4159	49	76	(	(	PUNCT
dpc-4159	49	77	33.3	33.3	NUM
dpc-4159	49	78	)	)	PUNCT
dpc-4159	49	79	86.3	86.3	NUM
dpc-4159	49	80	(	(	PUNCT
dpc-4159	49	81	40.3	40.3	NUM
dpc-4159	49	82	)	)	PUNCT
dpc-4159	49	83	83.1	83.1	NUM
dpc-4159	49	84	(	(	PUNCT
dpc-4159	49	85	32.5	32.5	NUM
dpc-4159	49	86	)	)	PUNCT
dpc-4159	49	87	87.4	87.4	NUM
dpc-4159	49	88	(	(	PUNCT
dpc-4159	49	89	19.3	19.3	NUM
dpc-4159	49	90	)	)	PUNCT
dpc-4159	49	91	baseline	baseline	NOUN
dpc-4159	49	92	-	-	PUNCT
dpc-4159	49	93	week	week	NOUN
dpc-4159	49	94	28	28	NUM
dpc-4159	49	95	pasi	pasi	NOUN
dpc-4159	49	96	reduction	reduction	NOUN
dpc-4159	49	97	≥75	≥75	NOUN
dpc-4159	49	98	%	%	NOUN
dpc-4159	49	99	,	,	PUNCT
dpc-4159	49	100	%	%	NOUN
dpc-4159	49	101	83.9	83.9	NUM
dpc-4159	49	102	87.9	87.9	NUM
dpc-4159	49	103	78.3	78.3	NUM
dpc-4159	49	104	81.4	81.4	NUM
dpc-4159	49	105	baseline	baseline	NOUN
dpc-4159	49	106	-	-	PUNCT
dpc-4159	49	107	week	week	NOUN
dpc-4159	49	108	28	28	NUM
dpc-4159	49	109	pasi	pasi	NOUN
dpc-4159	49	110	90	90	NUM
dpc-4159	49	111	%	%	NOUN
dpc-4159	49	112	decrease	decrease	NOUN
dpc-4159	49	113	,	,	PUNCT
dpc-4159	49	114	%	%	NOUN
dpc-4159	49	115	73.2	73.2	NUM
dpc-4159	49	116	76.9	76.9	NUM
dpc-4159	49	117	69.6	69.6	NUM
dpc-4159	49	118	70.0	70.0	NUM
dpc-4159	49	119	baseline	baseline	NOUN
dpc-4159	49	120	-	-	PUNCT
dpc-4159	49	121	week	week	NOUN
dpc-4159	49	122	28	28	NUM
dpc-4159	49	123	pasi	pasi	NOUN
dpc-4159	49	124	100	100	NUM
dpc-4159	49	125	%	%	NOUN
dpc-4159	49	126	decrease	decrease	NOUN
dpc-4159	49	127	,	,	PUNCT
dpc-4159	49	128	%	%	NOUN
dpc-4159	49	129	57.1	57.1	NUM
dpc-4159	49	130	61.1	61.1	NUM
dpc-4159	49	131	60.9	60.9	NUM
dpc-4159	49	132	48.6	48.6	NUM
dpc-4159	49	133	sd	sd	NOUN
dpc-4159	49	134	:	:	PUNCT
dpc-4159	49	135	standard	standard	ADJ
dpc-4159	49	136	deviation	deviation	NOUN
dpc-4159	49	137	;	;	PUNCT
dpc-4159	49	138	pasi	pasi	NOUN
dpc-4159	49	139	:	:	PUNCT
dpc-4159	49	140	psoriasis	psoriasis	NOUN
dpc-4159	49	141	area	area	NOUN
dpc-4159	49	142	severity	severity	PROPN
dpc-4159	49	143	index	index	NOUN
dpc-4159	49	144	.	.	PUNCT
dpc-4159	50	1	apatients	apatient	NOUN
dpc-4159	50	2	not	not	PART
dpc-4159	50	3	withdrawn	withdraw	VERB
dpc-4159	50	4	from	from	ADP
dpc-4159	50	5	anti	anti	ADJ
dpc-4159	50	6	-	-	ADJ
dpc-4159	50	7	il	il	ADJ
dpc-4159	50	8	23	23	NUM
dpc-4159	50	9	treatment	treatment	NOUN
dpc-4159	50	10	only	only	ADV
dpc-4159	50	11	.	.	PUNCT
dpc-4159	51	1	*	*	PUNCT
dpc-4159	51	2	chi	chi	ADJ
dpc-4159	51	3	-	-	PUNCT
dpc-4159	51	4	squared	square	VERB
dpc-4159	51	5	test	test	NOUN
dpc-4159	51	6	for	for	ADP
dpc-4159	51	7	categorical	categorical	ADJ
dpc-4159	51	8	variables	variable	NOUN
dpc-4159	51	9	;	;	PUNCT
dpc-4159	51	10	one	one	NUM
dpc-4159	51	11	-	-	PUNCT
dpc-4159	51	12	way	way	NOUN
dpc-4159	51	13	anova	anova	X
dpc-4159	51	14	with	with	ADP
dpc-4159	51	15	sidak	sidak	NOUN
dpc-4159	51	16	corrections	correction	NOUN
dpc-4159	51	17	for	for	ADP
dpc-4159	51	18	continuous	continuous	ADJ
dpc-4159	51	19	ones	one	NOUN
dpc-4159	51	20	.	.	PUNCT
dpc-4159	52	1	a	a	DET
dpc-4159	52	2	:	:	PUNCT
dpc-4159	52	3	p<0.05	p<0.05	NOUN
dpc-4159	52	4	for	for	ADP
dpc-4159	52	5	the	the	DET
dpc-4159	52	6	comparison	comparison	NOUN
dpc-4159	52	7	between	between	ADP
dpc-4159	52	8	patients	patient	NOUN
dpc-4159	52	9	treated	treat	VERB
dpc-4159	52	10	with	with	ADP
dpc-4159	52	11	guselkumab	guselkumab	NOUN
dpc-4159	52	12	and	and	CCONJ
dpc-4159	52	13	patients	patient	NOUN
dpc-4159	52	14	treated	treat	VERB
dpc-4159	52	15	with	with	ADP
dpc-4159	52	16	risankizumab	risankizumab	NOUN
dpc-4159	52	17	;	;	PUNCT
dpc-4159	52	18	b	b	X
dpc-4159	52	19	:	:	PUNCT
dpc-4159	52	20	p<0.05	p<0.05	NOUN
dpc-4159	52	21	for	for	ADP
dpc-4159	52	22	the	the	DET
dpc-4159	52	23	comparison	comparison	NOUN
dpc-4159	52	24	between	between	ADP
dpc-4159	52	25	patients	patient	NOUN
dpc-4159	52	26	treated	treat	VERB
dpc-4159	52	27	with	with	ADP
dpc-4159	52	28	guselkumab	guselkumab	NOUN
dpc-4159	52	29	and	and	CCONJ
dpc-4159	52	30	patients	patient	NOUN
dpc-4159	52	31	treated	treat	VERB
dpc-4159	52	32	with	with	ADP
dpc-4159	52	33	tildrakizumab	tildrakizumab	NOUN
dpc-4159	52	34	;	;	PUNCT
dpc-4159	52	35	c	c	X
dpc-4159	52	36	:	:	PUNCT
dpc-4159	52	37	p<0.05	p<0.05	NOUN
dpc-4159	52	38	for	for	ADP
dpc-4159	52	39	the	the	DET
dpc-4159	52	40	comparison	comparison	NOUN
dpc-4159	52	41	between	between	ADP
dpc-4159	52	42	patients	patient	NOUN
dpc-4159	52	43	treated	treat	VERB
dpc-4159	52	44	with	with	ADP
dpc-4159	52	45	risankizumab	risankizumab	NOUN
dpc-4159	52	46	and	and	CCONJ
dpc-4159	52	47	patients	patient	NOUN
dpc-4159	52	48	treated	treat	VERB
dpc-4159	52	49	with	with	ADP
dpc-4159	52	50	tildrakizumab	tildrakizumab	NOUN
dpc-4159	52	51	.	.	PUNCT
dpc-4159	53	1	all	all	DET
dpc-4159	53	2	p	p	NOUN
dpc-4159	53	3	-	-	PUNCT
dpc-4159	53	4	values	value	NOUN
dpc-4159	53	5	that	that	PRON
dpc-4159	53	6	are	be	AUX
dpc-4159	53	7	not	not	PART
dpc-4159	53	8	indicated	indicate	VERB
dpc-4159	53	9	were	be	AUX
dpc-4159	53	10	≥0.05	≥0.05	ADJ
dpc-4159	53	11	.	.	PUNCT
dpc-4159	53	12	4	4	NUM
dpc-4159	53	13	research	research	NOUN
dpc-4159	53	14	letter	letter	NOUN
dpc-4159	53	15	|	|	ADV
dpc-4159	53	16	dermatol	dermatol	ADJ
dpc-4159	53	17	pract	pract	NOUN
dpc-4159	53	18	concept	concept	NOUN
dpc-4159	53	19	.	.	PUNCT
dpc-4159	54	1	2024;14(3):e2024179	2024;14(3):e2024179	NUM
dpc-4159	54	2	advanced	advanced	ADJ
dpc-4159	54	3	age	age	NOUN
dpc-4159	54	4	do	do	AUX
dpc-4159	54	5	not	not	PART
dpc-4159	54	6	represent	represent	VERB
dpc-4159	54	7	either	either	CCONJ
dpc-4159	54	8	selection	selection	NOUN
dpc-4159	54	9	or	or	CCONJ
dpc-4159	54	10	exclusion	exclusion	NOUN
dpc-4159	54	11	criteria	criterion	NOUN
dpc-4159	54	12	for	for	ADP
dpc-4159	54	13	this	this	DET
dpc-4159	54	14	class	class	NOUN
dpc-4159	54	15	of	of	ADP
dpc-4159	54	16	drugs	drug	NOUN
dpc-4159	54	17	.	.	PUNCT
dpc-4159	55	1	il23	il23	ADJ
dpc-4159	55	2	inhibitors	inhibitor	NOUN
dpc-4159	55	3	showed	show	VERB
dpc-4159	55	4	no	no	DET
dpc-4159	55	5	significant	significant	ADJ
dpc-4159	55	6	safety	safety	NOUN
dpc-4159	55	7	findings	finding	NOUN
dpc-4159	55	8	and	and	CCONJ
dpc-4159	55	9	no	no	DET
dpc-4159	55	10	relevant	relevant	ADJ
dpc-4159	55	11	clinical	clinical	ADJ
dpc-4159	55	12	or	or	CCONJ
dpc-4159	55	13	laboratory	laboratory	NOUN
dpc-4159	55	14	side	side	NOUN
dpc-4159	55	15	-	-	PUNCT
dpc-4159	55	16	effects	effect	NOUN
dpc-4159	55	17	were	be	AUX
dpc-4159	55	18	recorded	record	VERB
dpc-4159	55	19	.	.	PUNCT
dpc-4159	56	1	the	the	DET
dpc-4159	56	2	incident	incident	NOUN
dpc-4159	56	3	events	event	NOUN
dpc-4159	56	4	that	that	PRON
dpc-4159	56	5	led	lead	VERB
dpc-4159	56	6	to	to	ADP
dpc-4159	56	7	treatment	treatment	NOUN
dpc-4159	56	8	suspension	suspension	NOUN
dpc-4159	56	9	,	,	PUNCT
dpc-4159	56	10	namely	namely	ADV
dpc-4159	56	11	a	a	DET
dpc-4159	56	12	diagnosis	diagnosis	NOUN
dpc-4159	56	13	of	of	ADP
dpc-4159	56	14	melanoma	melanoma	NOUN
dpc-4159	56	15	,	,	PUNCT
dpc-4159	56	16	concurrent	concurrent	ADJ
dpc-4159	56	17	urticaria	urticaria	NOUN
dpc-4159	56	18	and	and	CCONJ
dpc-4159	56	19	worsening	worsening	NOUN
dpc-4159	56	20	of	of	ADP
dpc-4159	56	21	the	the	DET
dpc-4159	56	22	arthritis	arthritis	NOUN
dpc-4159	56	23	,	,	PUNCT
dpc-4159	56	24	had	have	VERB
dpc-4159	56	25	no	no	DET
dpc-4159	56	26	correlation	correlation	NOUN
dpc-4159	56	27	with	with	ADP
dpc-4159	56	28	their	their	PRON
dpc-4159	56	29	administration	administration	NOUN
dpc-4159	56	30	.	.	PUNCT
dpc-4159	57	1	these	these	DET
dpc-4159	57	2	drugs	drug	NOUN
dpc-4159	57	3	did	do	AUX
dpc-4159	57	4	not	not	PART
dpc-4159	57	5	impact	impact	VERB
dpc-4159	57	6	on	on	ADP
dpc-4159	57	7	concomitant	concomitant	ADJ
dpc-4159	57	8	critical	critical	ADJ
dpc-4159	57	9	infectious	infectious	ADJ
dpc-4159	57	10	conditions	condition	NOUN
dpc-4159	57	11	or	or	CCONJ
dpc-4159	57	12	on	on	ADP
dpc-4159	57	13	cancer	cancer	NOUN
dpc-4159	57	14	history	history	NOUN
dpc-4159	57	15	.	.	PUNCT
dpc-4159	58	1	il23	il23	ADJ
dpc-4159	58	2	inhibitors	inhibitor	NOUN
dpc-4159	58	3	’	'	PUNCT
dpc-4159	58	4	favorable	favorable	ADJ
dpc-4159	58	5	safety	safety	NOUN
dpc-4159	58	6	profile	profile	NOUN
dpc-4159	58	7	accounts	account	VERB
dpc-4159	58	8	for	for	ADP
dpc-4159	58	9	the	the	DET
dpc-4159	58	10	very	very	ADV
dpc-4159	58	11	high	high	ADJ
dpc-4159	58	12	drug	drug	NOUN
dpc-4159	58	13	survival	survival	NOUN
dpc-4159	58	14	found	find	VERB
dpc-4159	58	15	in	in	ADP
dpc-4159	58	16	the	the	DET
dpc-4159	58	17	study	study	NOUN
dpc-4159	58	18	,	,	PUNCT
dpc-4159	58	19	which	which	PRON
dpc-4159	58	20	was	be	AUX
dpc-4159	58	21	close	close	ADJ
dpc-4159	58	22	to	to	ADP
dpc-4159	58	23	95	95	NUM
dpc-4159	58	24	%	%	NOUN
dpc-4159	58	25	.	.	PUNCT
dpc-4159	59	1	(	(	PUNCT
dpc-4159	59	2	1,2,3	1,2,3	NOUN
dpc-4159	59	3	)	)	PUNCT
dpc-4159	59	4	conclusion	conclusion	NOUN
dpc-4159	59	5	the	the	DET
dpc-4159	59	6	study	study	NOUN
dpc-4159	59	7	findings	finding	NOUN
dpc-4159	59	8	show	show	VERB
dpc-4159	59	9	that	that	SCONJ
dpc-4159	59	10	these	these	DET
dpc-4159	59	11	drugs	drug	NOUN
dpc-4159	59	12	are	be	AUX
dpc-4159	59	13	very	very	ADV
dpc-4159	59	14	effective	effective	ADJ
dpc-4159	59	15	,	,	PUNCT
dpc-4159	59	16	rapid	rapid	ADJ
dpc-4159	59	17	,	,	PUNCT
dpc-4159	59	18	well	well	ADV
dpc-4159	59	19	tolerated	tolerate	VERB
dpc-4159	59	20	,	,	PUNCT
dpc-4159	59	21	also	also	ADV
dpc-4159	59	22	in	in	ADP
dpc-4159	59	23	comorbid	comorbid	NOUN
dpc-4159	59	24	subjects	subject	NOUN
dpc-4159	59	25	.	.	PUNCT
dpc-4159	60	1	apart	apart	ADV
dpc-4159	60	2	from	from	ADP
dpc-4159	60	3	initial	initial	ADJ
dpc-4159	60	4	differences	difference	NOUN
dpc-4159	60	5	in	in	ADP
dpc-4159	60	6	rapidity	rapidity	NOUN
dpc-4159	60	7	,	,	PUNCT
dpc-4159	60	8	risankizumab	risankizumab	NOUN
dpc-4159	60	9	being	be	AUX
dpc-4159	60	10	more	more	ADV
dpc-4159	60	11	rapid	rapid	ADJ
dpc-4159	60	12	than	than	ADP
dpc-4159	60	13	guselkumab	guselkumab	NOUN
dpc-4159	60	14	and	and	CCONJ
dpc-4159	60	15	even	even	ADV
dpc-4159	60	16	more	more	ADV
dpc-4159	60	17	than	than	ADP
dpc-4159	60	18	tildrakizumab	tildrakizumab	VERB
dpc-4159	60	19	in	in	ADP
dpc-4159	60	20	the	the	DET
dpc-4159	60	21	early	early	ADJ
dpc-4159	60	22	treatment	treatment	NOUN
dpc-4159	60	23	stages	stage	NOUN
dpc-4159	60	24	,	,	PUNCT
dpc-4159	60	25	the	the	DET
dpc-4159	60	26	three	three	NUM
dpc-4159	60	27	drugs	drug	NOUN
dpc-4159	60	28	do	do	AUX
dpc-4159	60	29	not	not	PART
dpc-4159	60	30	differ	differ	VERB
dpc-4159	60	31	either	either	CCONJ
dpc-4159	60	32	in	in	ADP
dpc-4159	60	33	effectiveness	effectiveness	NOUN
dpc-4159	60	34	or	or	CCONJ
dpc-4159	60	35	in	in	ADP
dpc-4159	60	36	safety.(4,5	safety.(4,5	NOUN
dpc-4159	60	37	)	)	PUNCT
dpc-4159	60	38	the	the	DET
dpc-4159	60	39	overall	overall	ADJ
dpc-4159	60	40	very	very	ADV
dpc-4159	60	41	high	high	ADJ
dpc-4159	60	42	drug	drug	NOUN
dpc-4159	60	43	survival	survival	NOUN
dpc-4159	60	44	of	of	ADP
dpc-4159	60	45	il23	il23	PROPN
dpc-4159	60	46	inhibitors	inhibitor	NOUN
dpc-4159	60	47	observed	observe	VERB
dpc-4159	60	48	,	,	PUNCT
dpc-4159	60	49	allows	allow	VERB
dpc-4159	60	50	us	we	PRON
dpc-4159	60	51	to	to	PART
dpc-4159	60	52	consider	consider	VERB
dpc-4159	60	53	them	they	PRON
dpc-4159	60	54	optimal	optimal	ADJ
dpc-4159	60	55	therapeutic	therapeutic	ADJ
dpc-4159	60	56	options	option	NOUN
dpc-4159	60	57	in	in	ADP
dpc-4159	60	58	clinical	clinical	ADJ
dpc-4159	60	59	practice	practice	NOUN
dpc-4159	60	60	.	.	PUNCT
dpc-4159	61	1	(	(	PUNCT
dpc-4159	61	2	6	6	NUM
dpc-4159	61	3	)	)	PUNCT
dpc-4159	61	4	references	reference	NOUN
dpc-4159	61	5	1	1	NUM
dpc-4159	61	6	.	.	NOUN
dpc-4159	61	7	mastorino	mastorino	PROPN
dpc-4159	61	8	l	l	NOUN
dpc-4159	61	9	,	,	PUNCT
dpc-4159	61	10	dapavo	dapavo	VERB
dpc-4159	61	11	p	p	NOUN
dpc-4159	61	12	,	,	PUNCT
dpc-4159	61	13	susca	susca	PROPN
dpc-4159	61	14	s	s	PROPN
dpc-4159	61	15	,	,	PUNCT
dpc-4159	61	16	et	et	PROPN
dpc-4159	61	17	al	al	PROPN
dpc-4159	61	18	.	.	PROPN
dpc-4159	61	19	drug	drug	PROPN
dpc-4159	61	20	survival	survival	NOUN
dpc-4159	61	21	and	and	CCONJ
dpc-4159	61	22	clinical	clinical	ADJ
dpc-4159	61	23	effectiveness	effectiveness	NOUN
dpc-4159	61	24	of	of	ADP
dpc-4159	61	25	secukinumab	secukinumab	NOUN
dpc-4159	61	26	,	,	PUNCT
dpc-4159	61	27	ixekizumab	ixekizumab	NOUN
dpc-4159	61	28	,	,	PUNCT
dpc-4159	61	29	brodalumab	brodalumab	NOUN
dpc-4159	61	30	,	,	PUNCT
dpc-4159	61	31	guselkumab	guselkumab	NOUN
dpc-4159	61	32	,	,	PUNCT
dpc-4159	61	33	risankizumab	risankizumab	NOUN
dpc-4159	61	34	,	,	PUNCT
dpc-4159	61	35	tildrakizumab	tildrakizumab	NOUN
dpc-4159	61	36	for	for	ADP
dpc-4159	61	37	psoriasis	psoriasis	NOUN
dpc-4159	61	38	treatment	treatment	NOUN
dpc-4159	61	39	.	.	PUNCT
dpc-4159	62	1	j	j	PROPN
dpc-4159	62	2	dtsch	dtsch	PROPN
dpc-4159	62	3	dermatol	dermatol	NOUN
dpc-4159	62	4	ges	ge	NOUN
dpc-4159	62	5	.	.	PROPN
dpc-4159	62	6	2023	2023	NUM
dpc-4159	62	7	nov	nov	PROPN
dpc-4159	62	8	2	2	NUM
dpc-4159	62	9	.	.	PUNCT
dpc-4159	62	10	megna	megna	PROPN
dpc-4159	62	11	m	m	PROPN
dpc-4159	62	12	,	,	PUNCT
dpc-4159	62	13	tommasino	tommasino	PROPN
dpc-4159	62	14	n	n	CCONJ
dpc-4159	62	15	,	,	PUNCT
dpc-4159	62	16	potestio	potestio	NOUN
dpc-4159	62	17	l	l	NOUN
dpc-4159	62	18	,	,	PUNCT
dpc-4159	62	19	et	et	PROPN
dpc-4159	62	20	al	al	PROPN
dpc-4159	62	21	.	.	PUNCT
dpc-4159	63	1	real	real	ADJ
dpc-4159	63	2	-	-	PUNCT
dpc-4159	63	3	world	world	NOUN
dpc-4159	63	4	practice	practice	NOUN
dpc-4159	63	5	indirect	indirect	ADJ
dpc-4159	63	6	comparison	comparison	NOUN
dpc-4159	63	7	between	between	ADP
dpc-4159	63	8	guselkumab	guselkumab	NOUN
dpc-4159	63	9	,	,	PUNCT
dpc-4159	63	10	risankizumab	risankizumab	NOUN
dpc-4159	63	11	,	,	PUNCT
dpc-4159	63	12	and	and	CCONJ
dpc-4159	63	13	tildrakizumab	tildrakizumab	NOUN
dpc-4159	63	14	:	:	PUNCT
dpc-4159	63	15	results	result	VERB
dpc-4159	63	16	from	from	ADP
dpc-4159	63	17	an	an	DET
dpc-4159	63	18	italian	italian	ADJ
dpc-4159	63	19	28	28	NUM
dpc-4159	63	20	-	-	PUNCT
dpc-4159	63	21	week	week	NOUN
dpc-4159	63	22	retrospective	retrospective	ADJ
dpc-4159	63	23	study	study	NOUN
dpc-4159	63	24	.	.	PUNCT
dpc-4159	64	1	j	j	PROPN
dpc-4159	64	2	dermatolog	dermatolog	PROPN
dpc-4159	64	3	treat	treat	NOUN
dpc-4159	64	4	.	.	PUNCT
dpc-4159	65	1	2022;33:2813	2022;33:2813	NUM
dpc-4159	65	2	-	-	SYM
dpc-4159	65	3	2820	2820	NUM
dpc-4159	65	4	3	3	NUM
dpc-4159	65	5	.	.	PUNCT
dpc-4159	65	6	reich	reich	PROPN
dpc-4159	65	7	k	k	PROPN
dpc-4159	65	8	,	,	PUNCT
dpc-4159	65	9	gordon	gordon	PROPN
dpc-4159	65	10	kb	kb	PROPN
dpc-4159	65	11	,	,	PUNCT
dpc-4159	65	12	strober	strober	ADV
dpc-4159	65	13	b	b	NUM
dpc-4159	65	14	,	,	PUNCT
dpc-4159	65	15	et	et	PROPN
dpc-4159	65	16	al	al	PROPN
dpc-4159	65	17	.	.	PUNCT
dpc-4159	65	18	super	super	ADJ
dpc-4159	65	19	-	-	NOUN
dpc-4159	65	20	response	response	NOUN
dpc-4159	65	21	to	to	ADP
dpc-4159	65	22	guselkumab	guselkumab	VERB
dpc-4159	65	23	treatment	treatment	NOUN
dpc-4159	65	24	in	in	ADP
dpc-4159	65	25	patients	patient	NOUN
dpc-4159	65	26	with	with	ADP
dpc-4159	65	27	moderate	moderate	ADJ
dpc-4159	65	28	-	-	PUNCT
dpc-4159	65	29	to	to	ADP
dpc-4159	65	30	-	-	PUNCT
dpc-4159	65	31	severe	severe	ADJ
dpc-4159	65	32	psoriasis	psoriasis	NOUN
dpc-4159	65	33	:	:	PUNCT
dpc-4159	65	34	age	age	NOUN
dpc-4159	65	35	,	,	PUNCT
dpc-4159	65	36	body	body	NOUN
dpc-4159	65	37	weight	weight	NOUN
dpc-4159	65	38	,	,	PUNCT
dpc-4159	65	39	baseline	baseline	ADJ
dpc-4159	65	40	psoriasis	psoriasis	NOUN
dpc-4159	65	41	area	area	NOUN
dpc-4159	65	42	and	and	CCONJ
dpc-4159	65	43	severity	severity	NOUN
dpc-4159	65	44	index	index	NOUN
dpc-4159	65	45	,	,	PUNCT
dpc-4159	65	46	and	and	CCONJ
dpc-4159	65	47	baseline	baseline	PROPN
dpc-4159	65	48	investigator	investigator	NOUN
dpc-4159	65	49	’s	’s	PART
dpc-4159	65	50	global	global	ADJ
dpc-4159	65	51	assessment	assessment	NOUN
dpc-4159	65	52	scores	score	NOUN
dpc-4159	65	53	predict	predict	VERB
dpc-4159	65	54	complete	complete	ADJ
dpc-4159	65	55	skin	skin	NOUN
dpc-4159	65	56	clearance	clearance	NOUN
dpc-4159	65	57	.	.	PUNCT
dpc-4159	66	1	j	j	PROPN
dpc-4159	66	2	eur	eur	PROPN
dpc-4159	66	3	acad	acad	PROPN
dpc-4159	66	4	dermatol	dermatol	NOUN
dpc-4159	66	5	venereol	venereol	NOUN
dpc-4159	66	6	.	.	PUNCT
dpc-4159	67	1	2022	2022	NUM
dpc-4159	67	2	;	;	PUNCT
dpc-4159	67	3	36:2393	36:2393	NUM
dpc-4159	67	4	-	-	SYM
dpc-4159	67	5	2400	2400	NUM
dpc-4159	67	6	.	.	PUNCT
dpc-4159	68	1	4	4	X
dpc-4159	68	2	.	.	X
dpc-4159	68	3	elgaard	elgaard	PROPN
dpc-4159	68	4	cdb	cdb	PROPN
dpc-4159	68	5	,	,	PUNCT
dpc-4159	68	6	iversen	iversen	PROPN
dpc-4159	68	7	l	l	PROPN
dpc-4159	68	8	,	,	PUNCT
dpc-4159	68	9	hjuler	hjuler	PROPN
dpc-4159	68	10	kf	kf	PROPN
dpc-4159	68	11	.	.	PROPN
dpc-4159	68	12	guselkumab	guselkumab	PROPN
dpc-4159	68	13	,	,	PUNCT
dpc-4159	68	14	tildrakizumab	tildrakizumab	NOUN
dpc-4159	68	15	and	and	CCONJ
dpc-4159	68	16	risankizumab	risankizumab	NOUN
dpc-4159	68	17	in	in	ADP
dpc-4159	68	18	real	real	ADJ
dpc-4159	68	19	-	-	PUNCT
dpc-4159	68	20	world	world	NOUN
dpc-4159	68	21	setting	setting	NOUN
dpc-4159	68	22	:	:	PUNCT
dpc-4159	68	23	drug	drug	NOUN
dpc-4159	68	24	survival	survival	NOUN
dpc-4159	68	25	and	and	CCONJ
dpc-4159	68	26	effectiveness	effectiveness	NOUN
dpc-4159	68	27	in	in	ADP
dpc-4159	68	28	the	the	DET
dpc-4159	68	29	treatment	treatment	NOUN
dpc-4159	68	30	of	of	ADP
dpc-4159	68	31	psoriasis	psoriasis	NOUN
dpc-4159	68	32	and	and	CCONJ
dpc-4159	68	33	psoriatic	psoriatic	ADJ
dpc-4159	68	34	arthritis	arthritis	NOUN
dpc-4159	68	35	.	.	PUNCT
dpc-4159	69	1	j	j	PROPN
dpc-4159	69	2	dermatolog	dermatolog	PROPN
dpc-4159	69	3	treat	treat	NOUN
dpc-4159	69	4	.	.	PUNCT
dpc-4159	70	1	2022	2022	NUM
dpc-4159	70	2	6:1	6:1	NUM
dpc-4159	70	3	-	-	SYM
dpc-4159	70	4	24	24	NUM
dpc-4159	70	5	.	.	PUNCT
dpc-4159	71	1	5	5	NUM
dpc-4159	71	2	.	.	X
dpc-4159	71	3	ruggiero	ruggiero	PROPN
dpc-4159	72	1	a	a	DET
dpc-4159	72	2	,	,	PUNCT
dpc-4159	72	3	fabbrocini	fabbrocini	NOUN
dpc-4159	72	4	g	g	NOUN
dpc-4159	72	5	,	,	PUNCT
dpc-4159	72	6	cinelli	cinelli	PROPN
dpc-4159	72	7	e	e	PROPN
dpc-4159	72	8	,	,	PUNCT
dpc-4159	72	9	et	et	PROPN
dpc-4159	72	10	al	al	PROPN
dpc-4159	72	11	.	.	PUNCT
dpc-4159	73	1	real	real	ADJ
dpc-4159	73	2	world	world	NOUN
dpc-4159	73	3	practice	practice	VERB
dpc-4159	73	4	indirect	indirect	ADJ
dpc-4159	73	5	comparison	comparison	NOUN
dpc-4159	73	6	between	between	ADP
dpc-4159	73	7	guselkumab	guselkumab	NOUN
dpc-4159	73	8	and	and	CCONJ
dpc-4159	73	9	risankizumab	risankizumab	NOUN
dpc-4159	73	10	:	:	PUNCT
dpc-4159	73	11	results	result	NOUN
dpc-4159	73	12	from	from	ADP
dpc-4159	73	13	an	an	DET
dpc-4159	73	14	italian	italian	ADJ
dpc-4159	73	15	retrospective	retrospective	ADJ
dpc-4159	73	16	study	study	NOUN
dpc-4159	73	17	.	.	PUNCT
dpc-4159	74	1	dermatol	dermatol	NOUN
dpc-4159	74	2	ther	ther	ADV
dpc-4159	74	3	.	.	PUNCT
dpc-4159	75	1	2022;35	2022;35	NUM
dpc-4159	75	2	:	:	PUNCT
dpc-4159	75	3	e15214	e15214	ADJ
dpc-4159	75	4	.	.	NOUN
dpc-4159	76	1	6	6	NUM
dpc-4159	76	2	.	.	X
dpc-4159	76	3	gisondi	gisondi	PROPN
dpc-4159	76	4	p	p	NOUN
dpc-4159	76	5	,	,	PUNCT
dpc-4159	76	6	fargnoli	fargnoli	PROPN
dpc-4159	76	7	mc	mc	PROPN
dpc-4159	76	8	,	,	PUNCT
dpc-4159	76	9	amerio	amerio	ADP
dpc-4159	76	10	p	p	X
dpc-4159	76	11	,	,	PUNCT
dpc-4159	76	12	et	et	PROPN
dpc-4159	76	13	al	al	PROPN
dpc-4159	76	14	.	.	PUNCT
dpc-4159	77	1	italian	italian	ADJ
dpc-4159	77	2	adaptation	adaptation	NOUN
dpc-4159	77	3	of	of	ADP
dpc-4159	77	4	euroguiderm	euroguiderm	NOUN
dpc-4159	77	5	guideline	guideline	NOUN
dpc-4159	77	6	on	on	ADP
dpc-4159	77	7	the	the	DET
dpc-4159	77	8	systemic	systemic	ADJ
dpc-4159	77	9	treatment	treatment	NOUN
dpc-4159	77	10	of	of	ADP
dpc-4159	77	11	chronic	chronic	ADJ
dpc-4159	77	12	plaque	plaque	NOUN
dpc-4159	77	13	psoriasis	psoriasis	NOUN
dpc-4159	77	14	.	.	PUNCT
dpc-4159	78	1	ital	ital	PROPN
dpc-4159	78	2	j	j	PROPN
dpc-4159	78	3	dermatol	dermatol	PROPN
dpc-4159	78	4	venerol	venerol	PROPN
dpc-4159	78	5	.	.	PUNCT
dpc-4159	79	1	2022;157(suppl	2022;157(suppl	NUM
dpc-4159	79	2	.	.	NOUN
dpc-4159	79	3	1	1	NUM
dpc-4159	79	4	to	to	ADP
dpc-4159	79	5	no	no	NOUN
dpc-4159	79	6	.	.	PUNCT
dpc-4159	80	1	1):1	1):1	NUM
dpc-4159	80	2	-	-	SYM
dpc-4159	80	3	78	78	NUM
dpc-4159	80	4	.	.	PUNCT